# 2026年1月3日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 复发与难治性骨肉瘤临床试验设计的考量：美国食品药品监督管理局专题研讨会

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481339)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41481339
**DOI：** 10.1158/1078-0432.CCR-25-3282

### 第一部分 原文与翻译

**英文原标题：** Considerations for Clinical Trial Design in Relapsed and Refractory Osteosarcoma: An FDA Symposium.

> **英文摘要：**
> Osteosarcoma is the most common primary malignant bone tumor in children and adolescents, with a peak incidence coinciding with the pubertal growth spurt. Metastatic disease occurs in approximately 10 to 20% of newly-diagnosed patients, most commonly in the lung. While 5-year overall survival (OS) for patients with localized disease at diagnosis is approximately 70% after standard upfront treatment of multi-agent chemotherapy and surgical resection, patients with metastatic or recurrent disease have a 5-year OS of approximately 30% in the pediatric age group. Currently, there is no standard treatment or FDA-approved therapy for relapsed and refractory osteosarcoma. Progress in identifying promising new treatments has been limited by its complex disease biology and rarity, as well as unique challenges of clinical trial design including unreliability of objective response rate (ORR) as a predictor of drug activity. Given these challenges and the unmet need for new therapies, the FDA Oncology Center of Excellence hosted an educational symposium, "Current Challenges in Clinical Trial Design for Relapsed and Refractory Osteosarcoma," in May 2023. During this mini-symposium, patient advocates, regulators from the FDA, and academic thought leaders in the field of pediatric sarcoma discussed challenges in clinical trial design and implementation. Achieving progress in relapsed and refractory osteosarcoma will require intentional collaboration among all stakeholders to identify trial designs that are acceptable to patients and will provide sufficient evidence of efficacy and safety to support a marketing application. Herein, we summarize the key points and future directions discussed at this meeting.

> **中文摘要：**
> 骨肉瘤是儿童和青少年中最常见的原发性恶性骨肿瘤，其发病高峰与青春期生长突增相一致。约有10%至20%的新诊断患者出现转移性疾病，最常见的转移部位为肺部。对于诊断时为局限性病变的患者，经多药联合化疗和外科切除的标准初始治疗后，其5年总体生存率约为70%；而在儿童年龄组中，具有转移性或复发性疾病的患者5年总体生存率约为30%。目前，对于复发与难治性骨肉瘤尚无标准治疗方案或FDA批准的治疗药物。由于疾病生物学特性复杂且罕见，以及临床试验设计中存在的特殊挑战（如客观缓解率作为药物活性预测指标的不可靠性），在发现有前景的新疗法方面进展有限。鉴于这些挑战及对新疗法未被满足的需求，FDA肿瘤卓越中心于2023年5月举办了一场题为“复发与难治性骨肉瘤临床试验设计的当前挑战”的教育性专题研讨会。在此次小型研讨会上，患者代表、FDA监管专家以及儿童肉瘤领域的学术领袖共同探讨了临床试验设计与实施方面的挑战。推进复发与难治性骨肉瘤研究进展，需要所有利益相关方有意识地协作，确定既能被患者接受、又能提供充分疗效与安全性证据以支持药品注册申请的试验设计。本文总结了本次会议所讨论的要点与未来方向。

### 第二部分 AI 大师评价

本研究以复发和难治性骨肉瘤的临床试验设计为主题，系统总结了FDA专题研讨会的核心讨论。作者指出该类患者缺乏标准治疗及获批药物，且试验设计受制于疾病罕见性与生物学复杂性。论文强调需跨部门合作，探索能兼顾患者可接受性与监管可行性的创新研究方案。该综述在推动儿科肉瘤领域的临床试验设计规范化方面具有积极意义，但仅为专家讨论总结，尚缺乏具体可操作的设计示例与实证数据。

---

## 2. 一名具有豹纹样高代谢病灶的女性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481314)
**期刊：** JAMA oncology
**PMID：** 41481314
**DOI：** 10.1001/jamaoncol.2025.5766

### 第一部分 原文与翻译

**英文原标题：** A Woman With Hypermetabolic Lesions in a Leopardlike Pattern.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该病例报告聚焦于一名在影像学上呈现豹纹样高代谢病灶分布的女性患者，提示一种罕见或具有特殊代谢模式的癌症或系统性疾病。虽然文章未提供具体摘要，但依据标题推测，该研究可能探讨代谢显像异质性在诊断与鉴别诊断中的意义。此类病例具有重要的教学与影像诊断价值，为复杂代谢表现的临床判断提供了新视角。其局限性在于缺乏详细病理与随访信息，仍需更多病例与机制研究支撑。

---

## 3. 为晚期肢端黑色素瘤患者指明前行之路

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481313)
**期刊：** JAMA oncology
**PMID：** 41481313
**DOI：** 10.1001/jamaoncol.2025.5663

### 第一部分 原文与翻译

**英文原标题：** Enlightening a Path Forward for Patients With Advanced Acral Melanoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文作为《JAMA Oncology》刊载的评论或观点文章，旨在探讨晚期肢端黑色素瘤（Acral melanoma）患者未来的治疗方向与研究策略。尽管缺乏摘要，但标题暗示作者可能综合了当前疗法的局限性与潜在创新途径，如免疫治疗和靶向治疗的联合应用。该文的价值在于为这一特殊亚型黑色素瘤的诊治提供思考与前瞻性意见，推动精准医学在罕见皮肤癌中的落地。

---

## 4. 托瑞帕利单抗与达卡巴嗪作为掌跖型晚期黑色素瘤一线治疗的比较：MELATORCH Ⅲ期随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481311)
**期刊：** JAMA oncology
**PMID：** 41481311
**DOI：** 10.1001/jamaoncol.2025.5751

### 第一部分 原文与翻译

**英文原标题：** Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.

> **英文摘要：**
> IMPORTANCE: Programmed cell death 1 (PD-1) inhibitors have been the standard first-line treatment for advanced melanoma; however, their clinical benefit in advanced melanoma predominantly of acral subtype remains unclear.
> 
> OBJECTIVE: To evaluate the efficacy and safety of toripalimab (a PD-1 inhibitor) vs dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.
> 
> DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, positive-control phase 3 randomized clinical trial enrolled patients with advanced melanoma from January 22, 2018, to July 12, 2023. Eligible patients had histologically confirmed stage III or IV melanoma and no prior systemic therapy for advanced melanoma. Data were analyzed from September 23 to November 27, 2023.
> 
> INTERVENTION: Patients were randomized (1:1) to receive toripalimab, 240 mg, every 2 weeks for up to 2 years, or dacarbazine, 1000 mg/m2, every 3 weeks until disease progression or intolerable toxic effects. Patients in the dacarbazine group were allowed to receive toripalimab after radiographic disease progression.
> 
> MAIN OUTCOMES AND MEASURES: Progression-free survival (PFS) assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors, version 1.1.
> 
> RESULTS: The analysis included 256 patients (median [range] age, 58 [18-85] years; 113 females [44.3%] and 142 males [55.7%]), among whom 160 participants (62.7%) had acral melanoma; 127 were randomized to receive toripalimab and 128 to dacarbazine (1 patient was excluded for Good Clinical Practice violation). The median (range) follow-up period was 11.8 (0.1-62.5) months. Toripalimab significantly reduced the risk of disease progression or death by 29.2% (hazard ratio, 0.71; 95% CI, 0.53-0.95; P = .02) compared with dacarbazine as assessed by BICR . Consistent PFS benefit was observed in most predefined subgroups, including patients with acral subtype. The BICR-assessed objective response rate of 11.0% (95% CI, 6.2%-17.8%) vs 8.6% (95% CI, 4.4%-14.9%), and the median duration of response of 13.8 (95% CI, 5.9-not evaluable) months vs 6.9 (95% CI, 3.8-not evaluable) months, respectively, also favored toripalimab over dacarbazine. Grade 3 or worse treatment-related adverse events occurred in 36 patients (28.3%) receiving toripalimab, with the most common (≥3%) being increased lipase (11 patients [8.7%]), anemia (5 patients [3.9%]), increased γ-glutamyltransferase (4 patients [3.1%]), hyponatremia (4 patients [3.1%]), and increased blood triglycerides (4 patients [3.1%]).
> 
> CONCLUSIONS AND RELEVANCE: This phase 3 randomized clinical trial found that as a first-line treatment for advanced melanoma predominantly of acral subtype, toripalimab showed a significant PFS benefit over dacarbazine and an acceptable safety profile.
> 
> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03430297.

> **中文摘要：**
> 重要性：程序性细胞死亡蛋白1（PD-1）抑制剂已成为晚期黑色素瘤的一线标准治疗；然而，其在以掌跖型为主的晚期黑色素瘤中的临床获益尚未明确。
> 
> 目的：评估PD-1抑制剂托瑞帕利单抗与达卡巴嗪作为以掌跖型为主的晚期黑色素瘤一线治疗时的疗效与安全性。
> 
> 设计、研究地点与参与者：这项多中心、开放标签、阳性对照的Ⅲ期随机临床试验，于2018年1月22日至2023年7月12日期间纳入晚期黑色素瘤患者。入组标准为组织学确诊的Ⅲ期或Ⅳ期黑色素瘤，且未接受过系统性晚期治疗。数据分析时间为2023年9月23日至11月27日。
> 
> 干预措施：患者按1:1比例随机分配至托瑞帕利单抗组（每2周给予240 mg，最长2年）或达卡巴嗪组（每3周给予1000 mg/m2，直至疾病进展或出现不可耐受毒性）。达卡巴嗪组患者在影像学证实疾病进展后可转入托瑞帕利单抗治疗。
> 
> 主要结局与测量指标：无进展生存期（PFS），依据实体瘤疗效评价标准1.1版经盲法独立中央评审（BICR）评估。
> 
> 结果：最终分析纳入256例患者（中位年龄58岁［范围18–85岁］；女性113例［44.3%］，男性142例［55.7%］），其中160例（62.7%）为掌跖型黑色素瘤；127例随机接受托瑞帕利单抗，128例接受达卡巴嗪（1例因违反良好临床规范被排除）。中位随访期为11.8个月（范围0.1–62.5）。BICR评估显示，与达卡巴嗪相比，托瑞帕利单抗可显著降低疾病进展或死亡风险29.2%（风险比0.71；95%置信区间0.53–0.95；P = .02）。在大多数预设亚组中，包括掌跖型患者，均观察到一致的PFS获益。BICR评估的客观缓解率托瑞帕利单抗组为11.0%（95%置信区间6.2%–17.8%），达卡巴嗪组为8.6%（95%置信区间4.4%–14.9%）；中位缓解持续时间分别为13.8个月（95%置信区间5.9–未评估）与6.9个月（95%置信区间3.8–未评估），均倾向于托瑞帕利单抗组。托瑞帕利单抗组出现3级或更严重治疗相关不良事件的患者有36例（28.3%），最常见（≥3%）为脂肪酶升高（11例［8.7%］）、贫血（5例［3.9%］）、γ-谷氨酰转移酶升高（4例［3.1%］）、低钠血症（4例［3.1%］）及甘油三酯升高（4例［3.1%］）。
> 
> 结论与意义：这项Ⅲ期随机临床试验表明，作为以掌跖型为主的晚期黑色素瘤一线治疗，托瑞帕利单抗较达卡巴嗪显著改善无进展生存期，且具有可接受的安全性。
> 
> 试验注册：ClinicalTrials.gov编号：NCT03430297。

### 第二部分 AI 大师评价

本研究通过Ⅲ期多中心随机对照试验，对托瑞帕利单抗与达卡巴嗪在掌跖型晚期黑色素瘤中的一线治疗价值进行了直接比较。结果显示，托瑞帕利单抗显著延长了无进展生存期，并在多个亚组中呈一致获益，安全性可接受。研究为PD-1抑制剂在掌跖型黑色素瘤中的疗效提供了高级别证据，弥补了以往此人群临床证据不足的空白。局限性在于开放标签设计及随访时间相对较短，仍需长期生存与真实世界数据验证。

---

## 5. 米伐妥昔单抗索拉夫坦辛治疗期间的眼部毒性反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481303)
**期刊：** JAMA oncology
**PMID：** 41481303
**DOI：** 10.1001/jamaoncol.2025.5763

### 第一部分 原文与翻译

**英文原标题：** Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究聚焦于抗体药物偶联物米伐妥昔单抗索拉夫坦辛治疗过程中出现的眼部毒性问题。尽管摘要未公开，但基于标题可推测文章旨在分析此药的眼部安全性特征，可能包括不良反应类型、发生机制及管理方法。该主题对肿瘤靶向治疗的安全评估具有重要临床意义。研究有助于指导临床在平衡疗效与眼部安全之间的决策，但受限于缺乏公开方法与结果细节，难以全面评估其创新性与证据强度。

---

## 6. 美国癌症学会：宫颈癌筛查新指南

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481284)
**期刊：** JAMA
**PMID：** 41481284
**DOI：** 10.1001/jama.2025.23004

### 第一部分 原文与翻译

**英文原标题：** ACS: New Cervical Cancer Screening Guidelines.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要暂无提供。

### 第二部分 AI 大师评价

该文发表在《JAMA》，标题指向美国癌症学会最新发布的宫颈癌筛查指南。尽管暂无摘要信息，但可推测文章主要介绍更新的筛查推荐、目标人群及检测方法变化。指南可能基于最新证据重新评估了HPV检测与联合筛查策略的相对价值，对公共卫生政策与临床实践具有重要指导意义。然而，由于缺乏全文与摘要，目前无法评估具体方法学细节及其潜在局限。

---

## 7. 当免疫检查点抑制剂突破屏障：皮肤、胃肠道和肺部免疫相关不良事件的机制与挑战

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481270)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41481270
**DOI：** 10.1158/1078-0432.CCR-25-3352

### 第一部分 原文与翻译

**英文原标题：** When checkpoint inhibitors break barriers: Mechanisms and challenges of irAEs of the skin, gastrointestinal tract, and lung.

> **英文摘要：**
> Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy though their use is limited by immune-related adverse events (irAEs) - off-target immune responses that can impact any organ, frequently lead to ICI discontinuation, and require immunosuppressive therapy. Barrier organs including the skin, gastrointestinal tract, and lung are among the tissues most frequently impacted by irAEs. As barrier organs, these tissues share important functions in maintaining separation from the external environment, participating in gas and nutrient exchange, and initiating localized immune responses that balance protection with tolerance. Here, we highlight common immunologic features of these barrier organs and how they contribute to the immunopathogenesis of tissue-specific irAEs. We specifically review the contribution of T lymphocytes, myeloid cells, interferons, interleukins, androgens, autoantibodies, oxygenation, and dysbiosis to irAE pathogenesis. Finally, we identify gaps in the understanding of shared immunologic mechanisms across barrier irAEs and highlight how an interdisciplinary approach to irAE treatment would improve the survival and quality of life of patients with cancer.

> **中文摘要：**
> 免疫检查点抑制剂（ICIs）已彻底改变了癌症治疗，但其临床应用受到免疫相关不良事件（irAEs）的限制——这些事件是靶外免疫反应，可影响任何器官，经常导致 ICI 的停用，并需要免疫抑制治疗。包括皮肤、胃肠道和肺在内的屏障器官是 irAEs 最常受累的组织之一。作为屏障器官，这些组织在维持与外界环境的分离、参与气体和营养物质交换、以及启动局部免疫反应以平衡防御与耐受方面具有重要功能。本文重点阐述了这些屏障器官的共同免疫学特征及其对特异性组织 irAE 免疫发病机制的贡献。我们特别综述了 T 淋巴细胞、髓系细胞、干扰素、白细胞介素、雄激素、自身抗体、氧合状态及菌群失衡在 irAE 发病中的作用。最后，我们指出了目前对不同屏障器官间共享免疫机制的认识空白，并强调跨学科治疗方法对于改善癌症患者的生存率和生活质量的重要性。

### 第二部分 AI 大师评价

该研究综述了皮肤、胃肠道及肺部等屏障器官在免疫检查点抑制剂相关免疫不良事件（irAEs）中的关键作用机制。作者系统分析了多种免疫细胞、细胞因子、激素与微生态因素在 irAE 发病过程中的参与，并强调了这些机制的相互联系。文章的创新在于将不同屏障组织的免疫学共性进行整合，为理解跨器官 irAE 提供了新的框架。尽管以综述为主，缺乏实验性验证，但其理论深度与多学科视角为临床干预策略提供了重要参考。

---

## 8. 艾瑞布林用于转移性血管肉瘤和上皮样血管内皮瘤（EHE）患者的Ⅱ期研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481257)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41481257
**DOI：** 10.1158/1078-0432.CCR-25-3362

### 第一部分 原文与翻译

**英文原标题：** A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE).

> **英文摘要：**
> PURPOSE: Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these two vascular sarcomas in a pooled analysis of two parallel phase 2 studies.
> 
> PATIENTS AND METHODS: Patients over age 18 years with metastatic or recurrent angiosarcoma or EHE were treated with eribulin (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) until progression or unacceptable toxicity. The primary endpoint was objective response rate by RECIST 1.1.
> 
> RESULTS: 29 patients were accrued to the study, 25 (85%) having had prior taxane exposure. We observed an objective response rate (ORR) of 17% for angiosarcomas, with 6/23 (26%) patients achieving disease stability for greater than 6 months, and for EHE an ORR of 33% (2/6) with 2/6 continuing treatment for over 12 months. Five patients experienced a >1.3-fold time to progression ratio (TTP2/TTP1) on eribulin compared to the immediately prior therapy. Eribulin tolerability was consistent with published data.
> 
> CONCLUSIONS: Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity.

> **中文摘要：**
> 研究目的：血管肉瘤和上皮样血管内皮瘤（EHE）是两种罕见的血管性肉瘤，治疗选择有限。既往研究已显示这些组织类型对微管靶向药物具有敏感性。本研究通过对两个平行的Ⅱ期研究进行汇总分析，报告了艾瑞布林在这两类血管性肉瘤中的疗效和安全性。
> 
> 患者与方法：纳入年龄超过18岁、具有转移性或复发性血管肉瘤或EHE的患者，给予艾瑞布林治疗（每21天为一个周期，于第1天和第8天按1.4 mg/m2用药），直至疾病进展或出现不可接受的不良反应。主要终点为按照RECIST 1.1标准评估的客观缓解率（ORR）。
> 
> 结果：共入组29例患者，其中25例（85%）此前接受过紫杉类药物治疗。血管肉瘤患者的客观缓解率（ORR）为17%，其中6/23（26%）患者疾病稳定超过6个月；EHE患者的ORR为33%（2/6），其中2/6患者持续治疗超过12个月。5例患者在接受艾瑞布林治疗时的疾病进展时间比其最近一次治疗增加了超过1.3倍（TTP2/TTP1 > 1.3）。艾瑞布林的耐受性与已发表的数据一致。
> 
> 结论：艾瑞布林在这一主要接受过紫杉类药物治疗的患者群体中表现出临床活性。未来仍需进一步研究以确认其疗效。

### 第二部分 AI 大师评价

本研究评估了艾瑞布林在转移性血管肉瘤和上皮样血管内皮瘤中的疗效与安全性。结果显示，艾瑞布林在既往紫杉类治疗失败的患者中仍具有一定的临床活性和可接受的安全性。尤其是在EHE患者中观察到较高的客观缓解率及持久疗效。研究的创新之处在于针对两种罕见血管肉瘤进行联合分析，但样本量有限且缺乏对照组，需通过更大规模的临床试验进一步验证。

---

## 9. 统一模型：染色质结合的多组分癌性凝聚体

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481253)
**期刊：** Cancer research
**PMID：** 41481253
**DOI：** 10.1158/0008-5472.CAN-25-5871

### 第一部分 原文与翻译

**英文原标题：** A unified model: chromatin-bound multi-component onco-condensates.

> **英文摘要：**
> In cells, highly coordinated multivalent interactions give rise to discrete functional assemblies-commonly referred to as biomolecular condensates-that compartmentalize the molecular components required for specific biological reactions. These condensates are increasingly recognized as organizational entities with central roles in normal cellular regulation and in the pathogenesis of human cancers. In a recent issue of Cell, Datar and colleagues investigated the condensation of NPM1c, a common gene mutation in acute myeloid leukemias (AMLs). They demonstrated the necessity and sufficiency of NPM1c in forming nuclear condensates termed coordinating bodies (C-bodies), which show co-partitioning of a suite of transcriptional coactivators such as NUP98, KMT2A/MLL1, Menin and XPO1/CRM1. While C-bodies are necessary for driving NPM1c-mutant AMLs, blockade of the co-partitioned component within C-bodies, such as the XPO1/CRM1 or Menin interaction by inhibitors, significantly alters the condensate composition and functionality. Likewise, a systematic deletion study of various regions within NPM1c pointed to a role for the coordinated multivalent interaction in establishing the functional condensates, as previously reported in studies of the Wilms tumor-causing ENL mutants and AML-causing NUP98 onco-fusions. Co-mixing of C-bodies and condensates formed by the onco-fusion of NUP98 or KMT2A/MLL1 in cells suggested them to be biophysically indistinguishable, indicative of a shared pathogenic mechanism. Altogether, recent studies of multiple genetic drivers in human cancers have revealed a type of chromatin-bound multi-component onco-condensates, which shall motivate the development of onco-condensate disruptors that could potentially be used as the broad treatments for cancer.

> **中文摘要：**
> 在细胞中，高度协调的多价相互作用会形成离散的功能性组装结构——通常被称为生物分子凝聚体，它们对特定生物反应所需的分子组分进行分区。此类凝聚体正日益被认识为在正常细胞调控及人类癌症发病机制中发挥核心作用的组织性结构单元。在《Cell》杂志的近期一期中，Datar 及其同事研究了急性髓系白血病（AML）中常见基因突变 NPM1c 的凝聚行为。他们证明了 NPM1c 在形成称为协调体（C-体）的核内凝聚体中具有必要性和充分性，这些凝聚体中共分配了一系列转录共激活因子，如 NUP98、KMT2A/MLL1、Menin 和 XPO1/CRM1。虽然 C-体对于驱动 NPM1c 突变型 AML 是必需的，但通过抑制剂阻断 C-体内的共分配组分（例如 XPO1/CRM1 或 Menin 相互作用）会显著改变凝聚体的组成和功能。同样，对 NPM1c 各区域的系统性缺失研究表明，协调的多价相互作用在建立功能性凝聚体中起关键作用，这与此前关于 Wilms 肿瘤致病 ENL 突变体及 AML 致病 NUP98 癌性融合的研究结果一致。在细胞中，C-体与由 NUP98 或 KMT2A/MLL1 癌性融合形成的凝聚体混合后表现出物理性质上的不可区分性，提示其具有共同的致病机制。总体而言，近期对多种人类癌症遗传驱动因素的研究揭示了一类染色质结合的多组分癌性凝聚体，这一发现有望推动开发“癌性凝聚体破坏剂”，以期作为广谱抗癌治疗的新策略。

### 第二部分 AI 大师评价

该研究综述性地提出了一个统一模型，阐明了多种癌症基因驱动因素通过形成染色质结合的多组分癌性凝聚体来实现致瘤机制。通过对 NPM1c 及其相关共激活因子的凝聚作用的实验观察，研究揭示了“协调体”在急性髓系白血病病理过程中的关键作用。其创新之处在于整合不同致癌融合蛋白的物理与功能特征，提出它们可能共享相似的生物物理基础和致病机制。该发现为未来开发靶向凝聚体的抗癌药物提供了新的方向，但依然需要进一步的功能和在体验证。

---

## 10. 多中心组织学图像整合与多尺度深度学习支持的机器学习儿童肉瘤分类

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41481196)
**期刊：** Cancer research
**PMID：** 41481196
**DOI：** 10.1158/0008-5472.CAN-25-2275

### 第一部分 原文与翻译

**英文原标题：** Multicenter Histology Image Integration and Multiscale Deep Learning Support Machine Learning-Enabled Pediatric Sarcoma Classification.

> **英文摘要：**
> Pediatric sarcomas present diagnostic challenges due to their rarity and diverse subtypes, often requiring specialized pathology expertise and costly genetic tests. To overcome these barriers, we developed a computational pipeline leveraging deep learning methods to accurately classify pediatric sarcoma subtypes from digitized histology slides. To ensure classifier generalizability and minimize center-specific artifacts, a dataset comprising 867 whole slide images (WSIs) from three medical centers and the Children's Oncology Group (COG) was collected and harmonized. Multiple convolutional neural network (CNN) and vision transformer (ViT) architectures were systematically evaluated as feature extractors for SAMPLER-based WSI representations, and input parameters, such as tile size combinations and resolutions, were tested and optimized. The analysis showed that advanced ViT foundation models (UNI, CONCH) significantly outperformed earlier approaches, and incorporating multiscale features enhanced classification accuracy. The optimized models achieved high performance, distinguishing rhabdomyosarcoma (RMS) from non-rhabdomyosarcoma (NRSTS) with an AUC of 0.969 and differentiating RMS subtypes (alveolar vs. embryonal) with an AUC of 0.961. Additionally, a two-stage pipeline effectively identified scarce Ewing sarcoma images from other NRSTS (AUC 0.929). Compared to conventional transformer encoder architectures used for WSI representations, these SAMPLER based classifiers were three orders of magnitude faster to train, despite operating entirely without a GPU. This study highlights that digital histopathology paired with rigorous image harmonization provides a powerful solution for pediatric sarcoma classification.

> **中文摘要：**
> 由于儿童肉瘤的罕见性和亚型多样性，其诊断面临挑战，往往需要专业的病理学专长和高昂的基因检测。为克服这些障碍，我们开发了一条计算流程，利用深度学习方法从数字化组织切片中准确分类儿童肉瘤的亚型。为确保分类器的普适性并最小化中心特异性伪影，本研究收集并统一了来自三个医疗中心和儿童肿瘤学组（COG）的867张全切片图像（WSIs）数据集。研究系统评估了多种卷积神经网络（CNN）和视觉Transformer（ViT）架构，作为基于SAMPLER的WSI特征提取模型，并测试与优化了输入参数，如切块尺寸组合与分辨率。分析结果显示，先进的ViT基础模型（UNI、CONCH）显著优于早期方法，并且引入多尺度特征可进一步提升分类准确性。优化后的模型表现优异，可将横纹肌肉瘤（RMS）与非横纹肌肉瘤（NRSTS）区分，AUC为0.969，并可区分RMS的肺泡型与胚胎型亚型，AUC为0.961。此外，双阶段流程能有效从其他NRSTS中识别出罕见的尤文肉瘤图像（AUC为0.929）。与传统用于WSI表征的Transformer编码器结构相比，这些基于SAMPLER的分类器在完全不使用GPU的情况下，训练速度快了三个数量级。本研究强调，数字病理结合严格的图像统一处理为儿童肉瘤分类提供了一种强大的解决方案。

### 第二部分 AI 大师评价

该研究旨在利用多中心数字病理数据与多尺度深度学习整合方法，建立高效且通用的儿童肉瘤分类体系。作者通过SAMPLER框架评估了多种CNN与ViT模型，最终证明先进的ViT基础模型在分类性能上显著优于传统方法，同时具备极高的训练效率。研究成果不仅提升了稀有肉瘤亚型的识别准确性，也为跨中心病理数据的标准化分析提供了新路径。其创新性在于多尺度特征聚合与轻量化图像表示架构的结合，尽管仍需更大样本与临床验证，但为人工智能病理诊断提供了重要参考。

---

## 11. 编辑注：γ‑氨基丁酸通过环磷酸腺苷依赖性调控蛋白激酶A/细胞外信号调节激酶1/2通路抑制胆管癌生长。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41479303)
**期刊：** Cancer research
**PMID：** 41479303
**DOI：** 10.1158/0008-5472.CAN-25-4987

### 第一部分 原文与翻译

**英文原标题：** Editor's Note: γ-Aminobutyric Acid Inhibits Cholangiocarcinoma Growth by Cyclic AMP-Dependent Regulation of the Protein Kinase A/Extracellular Signal-Regulated Kinase 1/2 Pathway.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文为编辑说明，涉及γ‑氨基丁酸（GABA）在胆管癌生长调控中的作用机制。标题展示了研究聚焦于环磷酸腺苷（cAMP）依赖的蛋白激酶A/ERK1/2通路调控，提示GABA可能通过信号通路抑制肿瘤进展。虽然缺乏摘要和实验细节，但从标题可见其旨在深化对神经递质在肿瘤信号转导中调控作用的理解。该方向具有潜在的跨学科创新性，但仍需更多实验证据验证相关机制。

---

## 12. 编者按：肺部肿瘤抑制因子 GPCR5A 结合 EGFR 并抑制其效应信号传导。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41479302)
**期刊：** Cancer research
**PMID：** 41479302
**DOI：** 10.1158/0008-5472.CAN-25-4988

### 第一部分 原文与翻译

**英文原标题：** Editor's Note: Lung Tumor Suppressor GPCR5A Binds EGFR and Restrains Its Effector Signaling.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本篇为《Cancer Research》期刊的编者按，指出肺部肿瘤抑制因子 GPCR5A 能与表皮生长因子受体（EGFR）结合，并限制其下游信号通路的活化。该发现提示 GPCR5A 可能在非小细胞肺癌的分子调控中发挥关键作用，具有潜在的治疗靶点价值。尽管文章未提供完整研究摘要，但该主题预示了 GPCR 信号与 EGFR 通路交互的机制新方向。

---

## 13. 胰腺癌肺转移：测定其“首次呼吸”的时机

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41479301)
**期刊：** Cancer research
**PMID：** 41479301
**DOI：** 10.1158/0008-5472.CAN-25-4465

### 第一部分 原文与翻译

**英文原标题：** Lung Metastases in Pancreatic Cancer: Timing Their First Breath.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor survival rate. This is largely due to patients being diagnosed when the disease has already metastasized to other organs, most commonly the liver and lungs. For these patients, no effective treatment exists, and the 5-year survival rate is less than 5%. Despite its highly metastatic nature, the timing and mechanisms of metastasis formation in PDAC remain largely unknown. In this issue of Cancer Research, Lasse Opsahl and colleagues identify a role for premalignant pancreatic intraepithelial neoplasia (PanIN) lesions in lung premetastatic niche formation. By performing histology and single-cell RNA sequencing analyses of a KRASG12D inducible mouse model of PDAC, the authors identify pSTAT3+ fibroblasts in the lungs, but not the liver, upon PanIN formation. Notably, pSTAT3+ fibroblasts in the lungs are required for metastasis formation. Mechanistically, KRAS activation in the pancreatic epithelium and consequential IL6 release activate STAT3 in lung fibroblasts. Altogether, Lasse Opsahl and colleagues demonstrate that PanIN lesions prime the lungs to favor future malignant cell outgrowth before the development of a pancreatic tumor and that blocking the formation of this lung premetastatic niche impairs metastasis in mice. See related article by Lasse Opsahl et al., p. 22.

> **中文摘要：**
> 胰腺导管腺癌（PDAC）的生存率极低。这主要是因为患者在疾病已经转移至其他器官（最常见为肝脏和肺部）时才被诊断。对于这些患者，目前没有有效的治疗手段，且 5 年生存率低于 5%。尽管 PDAC 具有高度转移性，但其转移形成的时间及机制仍 largely 未知。在本期《Cancer Research》中，Lasse Opsahl 及其同事发现，胰腺上皮内瘤变（PanIN）这一癌前病变在肺部前转移微环境形成中发挥作用。通过对一种可诱导 KRASG12D 的 PDAC 小鼠模型进行组织学及单细胞 RNA 测序分析，作者发现，当发生 PanIN 形成时，肺部（而非肝脏）中出现了 pSTAT3+ 成纤维细胞。值得注意的是，肺部的 pSTAT3+ 成纤维细胞是转移形成所必需的。在机制层面，胰腺上皮中 KRAS 的激活以及随后的 IL6 释放会激活肺成纤维细胞中的 STAT3。总体而言，Lasse Opsahl 及其同事证明，PanIN 病变可在胰腺肿瘤形成之前使肺部处于有利于未来恶性细胞增殖的“预激”状态，而阻断这种肺部前转移微环境的形成可在小鼠中抑制转移。

### 第二部分 AI 大师评价

该研究聚焦于胰腺导管腺癌肺转移的早期机制，揭示了癌前 PanIN 病变即可通过 KRAS-IL6-STAT3 轴调动肺部成纤维细胞形成前转移微环境。作者利用小鼠模型结合组织学与单细胞转录组分析，精确定位了肺特异性的 pSTAT3+ 成纤维细胞群体。此发现首次提出远端器官的“预激”可能早于原发肿瘤形成，具有重要的肿瘤转移生物学意义。研究创新性强，但仍需验证在人类 PDAC 患者中的可转化性及临床相关性。

---

## 14. 细胞外囊泡靶向与摄取的生物学机制及其治疗潜力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41478877)
**期刊：** Nature reviews. Molecular cell biology
**PMID：** 41478877
**DOI：** 10.1038/s41580-025-00922-4

### 第一部分 原文与翻译

**英文原标题：** Biology and therapeutic potential of extracellular vesicle targeting and uptake.

> **英文摘要：**
> Extracellular vesicles (EVs) have gained significant attention owing to their role in pathophysiological processes and potential as therapeutic tools. EVs are small vesicles (30 nm-5 µm) containing specific cargo (proteins, nucleic acids and lipids) and are released from most cell types. Their capacity to target and induce phenotypical changes in recipient cells has established them as key mediators of intercellular communication. Although EV biogenesis is well studied, their uptake and fate in recipient cells are still poorly understood. In this Review, we focus on the cell biology underlying EV interactions with recipient cells and their intracellular fate. We discuss the mechanisms EVs use to achieve cell-specific targeting, cell signalling and functional cargo delivery and list the key challenges currently limiting our ability to harness these EVs into efficient therapeutic nanovehicles. We explore how our understanding of the molecular mechanisms supporting interactions of EVs with recipient cells and their functions herein can provide new strategies to use them for therapeutic approaches.

> **中文摘要：**
> 由于在病理生理过程中的作用及作为治疗工具的潜力，细胞外囊泡（EVs）已引起广泛关注。EVs 是包含特定货物（蛋白质、核酸和脂类）的微小囊泡（30 nm 至 5 µm），可由大多数细胞类型释放。它们能够靶向并诱导受体细胞的表型变化，使其成为细胞间通信的重要介导者。尽管关于 EV 生物发生的研究较为深入，但其被受体细胞摄取后的命运仍知之甚少。在本综述中，我们聚焦于支撑 EV 与受体细胞相互作用及其胞内命运的细胞生物学机制。我们讨论了 EV 实现细胞特异性靶向、触发细胞信号及递送功能性货物的机制，并列出了目前限制我们将 EVs 转化为高效治疗性纳米载体的关键挑战。我们进一步探讨，对 EV 与受体细胞相互作用及其功能的分子机制的深入理解，如何为其在治疗应用中的策略创新提供新的思路。

### 第二部分 AI 大师评价

该综述系统总结了细胞外囊泡在靶向和被受体细胞摄取过程中的分子与细胞机制，强调其在疾病治疗中的潜在应用。作者基于现有研究进展，归纳了 EV 实现细胞特异性递送和信号传导的关键途径，同时指出了目前影像追踪和功能验证的限制。文章的创新之处在于将 EV 的生物学行为与治疗工程学视角相结合，为未来开发精准的纳米治疗载体提供了概念性框架。整体内容兼具机制深入性与应用前瞻性。

---

## 15. 肿瘤 PD-L1 诱导 β2m 泛素化与降解以促进癌细胞免疫逃逸

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41478857)
**期刊：** Cell research
**PMID：** 41478857
**DOI：** 10.1038/s41422-025-01205-5

### 第一部分 原文与翻译

**英文原标题：** Tumor PD-L1 induces β2m ubiquitylation and degradation for cancer cell immune evasion.

> **英文摘要：**
> Resistance to anti-PD-1/PD-L1 immune checkpoint blockade continues to be a critical challenge undermining its therapeutic efficacy in clinical applications. Most of the resistance mechanisms characterized to date have predominantly involved external factors beyond PD-L1. Here, we unexpectedly discovered that PD-L1 itself possesses E3 ubiquitin ligase activity to induce β2m ubiquitylation and subsequent degradation, which notably reduces MHC-I levels on the surface of tumor cells and antigen-presenting cells, thereby contributing to tumor cell evasion of recognition by CD8 T cells and ultimately resulting in resistance to anti-PD-1/PD-L1 immunotherapy, particularly in tumors with low basal β2m expression. Disrupting the E3 ubiquitin ligase activity of PD-L1 or interfering with the PD-L1-β2m interaction dramatically enhanced the sensitivity of tumor cells to PD-L1 blockade therapy. Our study reveals a previously unknown function of PD-L1 in the immune evasion of tumor cells, expanding our understanding of intrinsic resistance mechanisms to immune checkpoint blockade therapy.

> **中文摘要：**
> 针对抗 PD-1/PD-L1 免疫检查点阻断治疗的耐药性依然是临床应用中削弱其治疗效果的重要挑战。目前已被阐明的大多数耐药机制主要涉及 PD-L1 之外的外部因素。本文中，我们意外发现 PD-L1 本身具有 E3 泛素连接酶活性，能够诱导 β2m 的泛素化及其随后降解，从而显著降低肿瘤细胞和抗原呈递细胞表面的 MHC-I 水平，这一过程促使肿瘤细胞逃避 CD8 T 细胞的识别，最终导致抗 PD-1/PD-L1 免疫治疗的耐药，尤其是在基础 β2m 表达较低的肿瘤中更为显著。破坏 PD-L1 的 E3 泛素连接酶活性或干扰 PD-L1 与 β2m 的相互作用，可显著增强肿瘤细胞对 PD-L1 阻断疗法的敏感性。本研究揭示了 PD-L1 在肿瘤细胞免疫逃逸中的一种此前未知的新功能，扩展了我们对免疫检查点阻断疗法内在耐药机制的理解。

### 第二部分 AI 大师评价

本研究揭示了肿瘤 PD-L1 的一种非传统功能，即其具备 E3 泛素连接酶活性，可直接介导 β2m 泛素化和降解，导致 MHC-I 下调并促进免疫逃逸。研究通过分子机制层面解释了部分抗 PD-1/PD-L1 疗法耐药的内在原因，并提出干预 PD-L1-β2m 互作或其泛素化功能可增强免疫治疗敏感性。该发现具有重要创新性，为优化免疫检查点阻断疗法提供了潜在新策略，但其临床可行性和安全性仍需进一步验证。

---

## 16. 在能量危机期间，TECPR1 介导的膜管化修复受损溶酶体。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41478856)
**期刊：** Cell research
**PMID：** 41478856
**DOI：** 10.1038/s41422-025-01193-6

### 第一部分 原文与翻译

**英文原标题：** Repair of damaged lysosomes by TECPR1-mediated membrane tubulation during energy crisis.

> **英文摘要：**
> Lysosomes are essential for cellular homeostasis, serving as degradative organelles that recycle nutrients. Whether and how lysosomes maintain membrane integrity under energy stress is poorly understood. Here, we found that the uptake of lipid droplets by lysosomes during glucose starvation provokes disruption of lysosomal membranes. We identified tectonin beta-propeller repeat-containing protein 1 (TECPR1) as a critical mediator of lysosomal repair during glucose starvation or LLOMe-induced lysosomal membrane permeabilization. TECPR1 is recruited to damaged lysosomes via interaction with PI4P on damaged lysosomal membranes. It interacts with KIF1A to facilitate tubule formation from damaged lysosomes, enabling the removal of damaged membrane components and promoting lysosomal repair. Our in vitro reconstituted tubulation process provided further evidence that TECPR1 coordinates with KIF1A to drive tubulation from PI4P-enriched giant unilamellar vesicles. TECPR1-mediated lysosomal repair is essential for maintaining lipid metabolism and cellular survival during an energy crisis, as TECPR1 deficiency exacerbates starvation-induced liver damage in a high-fat diet-induced MAFLD mouse model. Our findings demonstrate a previously unrecognized role of TECPR1 in lysosomal repair, revealing its critical contributions to energy stress adaptation and liver protection. This work provides new insight into mechanisms of lysosomal repair and their implications for metabolic and lysosome-related disorders.

> **中文摘要：**
> 溶酶体对于维持细胞内稳态至关重要，作为降解性细胞器，其功能是循环再利用营养物质。然而，在能量应激下溶酶体如何维持膜完整性知之甚少。在本研究中，我们发现，在葡萄糖饥饿期间，溶酶体对脂滴的摄入会诱发溶酶体膜的破裂。我们鉴定出含有 tectonin β-螺旋片重复结构域的蛋白质 TECPR1，是在葡萄糖饥饿或 LLOMe 诱导的溶酶体膜通透化过程中介导溶酶体修复的关键分子。TECPR1 通过与受损溶酶体膜上的 PI4P 相互作用被招募至受损的溶酶体。它与 KIF1A 相互作用，促进受损溶酶体的膜管形成，从而实现受损膜成分的清除并促进溶酶体修复。我们体外重建的膜管化过程进一步证明，TECPR1 与 KIF1A 协同作用，从富含 PI4P 的巨大单层囊泡中驱动膜管形成。TECPR1 介导的溶酶体修复对于维持能量危机下的脂质代谢及细胞存活至关重要，因为 TECPR1 缺失会在高脂饮食诱导的 MAFLD 小鼠模型中加剧饥饿诱导的肝损伤。我们的研究揭示了 TECPR1 在溶酶体修复中此前未被认识的作用，表明其在能量应激适应与肝脏保护中的关键贡献。本研究为理解溶酶体修复机制及其在代谢性与溶酶体相关疾病中的启示提供了新的视角。

### 第二部分 AI 大师评价

该研究旨在阐明细胞在能量危机时维持溶酶体膜完整性的分子机制。研究者发现 TECPR1 通过与 PI4P 及 KIF1A 协同作用促进膜管形成，从而修复受损的溶酶体，维护脂质代谢平衡。该研究采用细胞及体外重建系统验证机制，并在动物模型中证实其生理意义。结果揭示了 TECPR1 在能量应激适应和肝脏保护中的新作用，为代谢性与溶酶体相关疾病研究开辟了新方向，但仍需进一步阐明其调控网络和临床转化潜力。

---

## 17. 对白血病的遗传性抗性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477906)
**期刊：** Science (New York, N.Y.)
**PMID：** 41477906
**DOI：** 10.1126/science.aed5244

### 第一部分 原文与翻译

**英文原标题：** Genetic resistance to leukemia.

> **英文摘要：**
> A genome-wide association study identifies a genetic variant that reduces the risk of leukemia.

> **中文摘要：**
> 一项全基因组关联研究发现了一种可降低白血病风险的遗传变异。

### 第二部分 AI 大师评价

本研究旨在通过全基因组关联分析探究对白血病的遗传抵抗机制，识别出可能降低白血病风险的关键遗传变异。该发现为阐明白血病的发病机制及人群易感差异提供了新的遗传学证据。研究结果有助于未来在精准医学中开发具有预测或预防潜力的遗传标记。然而，其功能机制及在不同人群中的普适性仍需进一步验证。

---

## 18. SPARK-seq：一种用于适配体发现与动力学特征分析的高通量平台

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477891)
**期刊：** Science (New York, N.Y.)
**PMID：** 41477891
**DOI：** 10.1126/science.adv6127

### 第一部分 原文与翻译

**英文原标题：** SPARK-seq: A high-throughput platform for aptamer discovery and kinetic profiling.

> **英文摘要：**
> Cell surface proteins are key disease biomarkers and therapeutic targets, yet high-throughput methods for aptamer discovery targeting these proteins in situ remain limited. We introduce single-cell perturbation-driven aptamer recognition and kinetics sequencing (SPARK-seq), a high-throughput platform integrating single-cell messenger RNA and aptamer sequencing with CRISPR-based surface protein perturbation. In a single experiment, SPARK-seq simultaneously mapped 5535 distinct aptamers to eight surface proteins, capturing interactions across more than two orders of magnitude in protein abundance and spanning diverse biophysical classes. The method discriminated closely related paralogous proteins with no detectable cross-reactivity and provided kinetic information that enabled the prioritization of aptamers with slow dissociation rates. Leveraging this kinetic diversity, we engineered variants with improved off-rate properties. SPARK-seq establishes a platform for high-efficiency discovery and rational variant design of aptamers and functional nucleic acids, unlocking possibilities in diagnostics and therapeutics.

> **中文摘要：**
> 细胞表面蛋白是关键的疾病生物标志物和治疗靶点，但针对这些蛋白质进行原位适配体筛选的高通量方法仍然有限。我们提出了单细胞扰动驱动的适配体识别与动力学测序（SPARK-seq），这是一种将单细胞信使 RNA 与适配体测序及基于 CRISPR 的表面蛋白干扰相结合的高通量平台。在一次实验中，SPARK-seq 同时将 5535 种不同的适配体映射至 8 种表面蛋白，捕获了跨越两个数量级以上蛋白丰度范围的相互作用，并覆盖了多种生物物理类别。该方法能够区分密切相关的旁系同源蛋白且无可检测的交叉反应，并提供了动力学信息，使得能够优先筛选具有较慢解离速率的适配体。利用这种动力学多样性，我们进一步构建了具有改进解离速率特性的变体。SPARK-seq 建立了一种用于高效适配体及功能性核酸发现与理性变体设计的平台，为诊断与治疗应用开辟了新的可能性。

### 第二部分 AI 大师评价

本研究旨在开发一种高通量、整合多组学信息的适配体筛选平台 SPARK-seq。该方法通过结合单细胞转录组测序与 CRISPR 介导的表面蛋白扰动，实现了适配体识别与动力学特征的并行测定。研究团队在单次实验中成功映射数千种适配体，并揭示了它们与目标蛋白间的丰度依赖性和生物物理多样性。该技术不仅能分辨相近的同源蛋白，还能依据动力学参数筛选高稳定性的适配体，展示出显著的创新性与应用潜力。其局限可能在于实验复杂度较高及对仪器整合的依赖。

---

## 19. 通过调控干细胞RNA调节机制实现对克隆性造血的遗传性抗性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477881)
**期刊：** Science (New York, N.Y.)
**PMID：** 41477881
**DOI：** 10.1126/science.adx4174

### 第一部分 原文与翻译

**英文原标题：** Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation.

> **英文摘要：**
> Somatic mutations that increase the fitness of hematopoietic stem cells (HSCs) drive their expansion in clonal hematopoiesis (CH) and predispose individuals to blood cancers. Population variation in the growth rate and potential of mutant clones suggests that genetic factors may confer resilience against CH. Here, we identified a noncoding regulatory variant, rs17834140-T, that protects against CH and myeloid malignancies by selectively down-regulating the RNA-binding protein MSI2 in HSCs. By modeling variant effects and mapping MSI2 binding targets, we uncovered an RNA network that maintains human HSCs and influences CH risk. Variant rs17834140-T was associated with slower CH expansion, and stem cell MSI2 levels modified -mutant HSC clonal dominance. These findings leverage natural resilience to illuminate posttranscriptional regulation in human HSCs, suggesting that inhibition of MSI2 or its targets could be rational strategies for blood cancer prevention.

> **中文摘要：**
> 增加造血干细胞（HSCs）适应性的体细胞突变会驱动其在克隆性造血（CH）中的扩增，并使个体更易发生血液癌症。群体中突变克隆的生长速率及潜能差异提示遗传因素可能赋予对CH的抗性。在本研究中，我们鉴定出一个非编码调控变异rs17834140-T，其通过在HSCs中选择性下调RNA结合蛋白MSI2，从而对CH及髓系恶性肿瘤具有保护作用。通过建立变异效应模型并绘制MSI2结合靶点图谱，我们揭示了一个维持人类HSC功能并影响CH风险的RNA网络。变异rs17834140-T与CH扩增速度减缓相关，且干细胞中MSI2水平能够调节突变HSC克隆优势。这些发现利用天然抗性揭示了人类HSC转录后调控机制，提示抑制MSI2或其靶标可能成为预防血液癌症的合理策略。

### 第二部分 AI 大师评价

该研究旨在阐明遗传因素如何影响克隆性造血的发生风险。通过全基因组分析与功能建模，作者发现rs17834140-T变异可通过抑制造血干细胞中的MSI2蛋白表达，从而减缓突变克隆的扩增。研究揭示了一个维系HSC稳态并决定CH风险的RNA调控网络，深化了对转录后层面造血调控的理解。该结果不仅从遗传层面解释了个体间CH易感性的差异，也为利用MSI2抑制策略进行血液癌症预防提供了新思路。

---

## 20. 工程化锚定适配体诱导转录因子的重新定位与功能失活

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477872)
**期刊：** Science advances
**PMID：** 41477872
**DOI：** 10.1126/sciadv.adw6496

### 第一部分 原文与翻译

**英文原标题：** Engineered anchoring aptamers induce relocalization and functional inactivation of transcription factors.

> **英文摘要：**
> Proper nucleocytoplasmic distribution of transcription factors (TFs) is crucial for cellular homeostasis. Mislocalization of TFs contributes to cancers, making TF relocalization a promising anticancer therapeutic strategy. We engineered anchoring aptamers as a platform for relocalizing TFs. Anchoring aptamers are heterobifunctional nucleic acids consisting of two ligands joined by a linker: one targeting the plasma membrane-anchored protein and the other recruiting the TF. As a proof of concept, we used the Ra1 aptamer targeting Ras and the DNA ligand specific for p65 or E2F1 to construct anchoring aptamers. Simultaneous binding of the anchoring aptamers to Ras and either p65 or E2F1 effectively induces cytoplasmic relocalization and functional inactivation of p65 or E2F1. Using a lentiviral expression system of anchoring aptamers, we achieved sustained cytoplasmic retention of p65 and marked inhibition of tumor growth. This work establishes a universal platform for TF relocalization, offering promising opportunities for innovative anticancer therapeutic strategies.

> **中文摘要：**
> 转录因子（TFs）的核质分布对于细胞稳态至关重要。转录因子的定位错误会促成癌症的发生，使得TF重新定位成为一种有前景的抗癌治疗策略。我们设计了锚定适配体作为转录因子重新定位的平台。锚定适配体是由连接子连接的两种配体组成的杂双功能核酸：一种靶向质膜锚定蛋白，另一种则招募转录因子。作为概念验证，我们利用靶向Ras的Ra1适配体以及分别特异识别p65或E2F1的DNA配体构建了锚定适配体。锚定适配体同时结合Ras与p65或E2F1，能够有效诱导p65或E2F1的细胞质重新定位及功能失活。利用锚定适配体的慢病毒表达系统，我们实现了p65在细胞质中的持续滞留，并显著抑制了肿瘤生长。本研究建立了一个通用的转录因子重新定位平台，为创新性抗癌治疗策略提供了有前景的机遇。

### 第二部分 AI 大师评价

该研究旨在通过工程化设计锚定适配体，调控转录因子在细胞内的空间分布，从而实现其功能失活。作者通过构建能同时结合Ras与转录因子p65或E2F1的双功能核酸，实现了转录因子的细胞质重新定位。实验结果表明，该系统可诱导持续的转录因子滞留并抑制肿瘤生长。研究创新地提出了利用核酸工程手段精确调控信号分子定位的治疗策略，为抗癌药物开发带来新的思路，但仍需进一步验证其体内安全性与适用性。

---

## 21. HLA-Shuttle：一种用于增强免疫冷肿瘤中抗原呈递的系统

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477871)
**期刊：** Science advances
**PMID：** 41477871
**DOI：** 10.1126/sciadv.aeb0821

### 第一部分 原文与翻译

**英文原标题：** HLA-Shuttle: A system for enhancing antigen presentation in immunologically cold tumors.

> **英文摘要：**
> Epitopic peptides presented by class-I human leukocyte antigen (HLA-I) proteins provide the basis of immune surveillance by T cells. Conversely, reduced surface HLA-I expression is a hallmark of immune evasion by latent viral infections and cancer, which confounds the identification of peptide antigens and neoantigens. Here, we outline a system (HLA-Shuttle) for in vitro manipulation of cells with engineered components of the HLA-I processing machinery to confer a continuum of chaperoning activity throughout their trafficking pathway. HLA-Shuttle restores antigen presentation in immunologically cold neuroblastoma cells, enabling identification of multiple tumor-associated antigens with therapeutic potential. Cellular trafficking assays and single-particle tracking reveal a global stabilization of HLA-I molecules, extension of their cell-surface lifetime and microdomain formation. HLA-Shuttle can be used across a range of aberrant cellular states where low antigen expression remains a bottleneck for the identification of endogenous peptide antigens.

> **中文摘要：**
> 由I类人白细胞抗原（HLA-I）蛋白呈递的表位肽为T细胞的免疫监视提供了基础。相反，表面HLA-I表达的降低是潜伏性病毒感染和癌症免疫逃逸的标志，这使得肽抗原和新抗原的识别变得复杂。在此，我们提出一个系统（HLA-Shuttle），通过在体外操控细胞中HLA-I加工机制的工程化组分，使其在整个转运通路上都具有连续的伴侣活性。HLA-Shuttle可在免疫冷的神经母细胞瘤细胞中恢复抗原呈递，从而识别出具有治疗潜力的多种肿瘤相关抗原。细胞转运分析和单粒子追踪揭示了HLA-I分子的整体稳定化、其细胞表面寿命的延长以及微域结构的形成。HLA-Shuttle可应用于多种抗原表达低下的异常细胞状态，在这些状态下，低抗原呈递仍是识别内源性肽抗原的瓶颈。

### 第二部分 AI 大师评价

该研究旨在解决免疫冷肿瘤中抗原呈递缺陷的问题，提出了利用工程化HLA-I加工机制的“HLA-Shuttle”系统。该系统在体外可增强细胞内HLA-I伴侣活性，从而提升抗原展示能力。实验显示其能在神经母细胞瘤细胞中恢复抗原呈递，促进多个具有治疗潜力的肿瘤相关抗原的识别。其创新性在于通过调控HLA分子加工与转运，实现抗原呈递功能的全程增强，为免疫治疗提供了新方向，但其在体内应用的可行性仍需进一步验证。

---

## 22. 针对膀胱癌的靶向抗体–药物偶联物的表型发现与治疗评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477868)
**期刊：** Science advances
**PMID：** 41477868
**DOI：** 10.1126/sciadv.ady0041

### 第一部分 原文与翻译

**英文原标题：** Phenotypic discovery and therapeutic evaluation of an -targeting antibody-drug conjugate for bladder cancer.

> **英文摘要：**
> Antibody-drug conjugates (ADCs) require antibodies with both high specificity and efficient internalization, features often overlooked by conventional discovery pipelines that rely on preselected antigens and recombinant proteins. Here, we describe an integrated phenotypic platform that combines target-unbiased live-cell biopanning with in situ chemical cross-linking and mass spectrometry to concurrently identify internalizing antibodies and their membrane-bound cognate antigens in a native cellular context. Using this approach, we identified 2E7, an antibody with rapid internalization and specificity for the integrin α3β1 () heterodimer. Integrated transcriptomic and proteomic analyses revealed pronounced overexpression of  across multiple solid tumors, with particularly elevated levels in aggressive bladder cancer subtypes. A 2E7-MMAE (monomethyl auristatin E) ADC exhibited potent, dose-dependent antitumor activity in bladder cancer xenograft models, leading to tumor regression and prolonging survival. This study establishes a generalizable framework for function-first ADC discovery and nominates  as a promising therapeutic target in bladder cancer.

> **中文摘要：**
> 抗体–药物偶联物（ADC）需要兼具高特异性与高效内化能力的抗体，而这些特性往往在依赖预选抗原与重组蛋白的传统发现流程中被忽视。本文描述了一种综合表型筛选平台，该平台将无靶点偏倚的活细胞生物筛选与原位化学交联和质谱分析相结合，可在原生细胞环境中同时鉴定内化抗体及其膜结合的相应抗原。利用该方法，研究者鉴定出抗体2E7，其具有快速内化能力并特异性识别整合素α3β1异源二聚体。整合的转录组学与蛋白质组学分析显示，该靶标在多种实体瘤中显著高表达，尤其在侵袭性膀胱癌亚型中表达水平更高。2E7-MMAE（单甲基奥瑞他汀E）ADC在膀胱癌异种移植模型中表现出强效、剂量依赖的抗肿瘤活性，可诱导肿瘤退缩并延长生存期。本研究建立了一种以功能优先的ADC发现通用框架，并提出该靶标有望作为膀胱癌的潜在治疗靶点。

### 第二部分 AI 大师评价

该研究旨在通过表型驱动的方法发现新的抗体–药物偶联物（ADC）靶点并评估其治疗潜力。团队开发了一种融合化学交联、质谱与活细胞筛选的整合平台，无需预设抗原即可同时鉴定内化抗体及其天然配体。结果发现的2E7抗体具有优异的内化特性与靶向性，其构建的2E7-MMAE偶联物在膀胱癌模型中展现出显著疗效。该研究的创新性在于突破了传统ADC发现对靶标预设的依赖，提出了“功能优先”的新策略，但仍需在临床前安全性与广谱适用性方面进一步验证。

---

## 23. 人类FcRL5是一种可同时结合两种IgG的Fc受体

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477863)
**期刊：** Science advances
**PMID：** 41477863
**DOI：** 10.1126/sciadv.aeb8865

### 第一部分 原文与翻译

**英文原标题：** Human FcRL5 is an Fc receptor that simultaneously engages two IgGs.

> **英文摘要：**
> The Fc receptors play crucial roles in initiating the effector functions of immunoglobulins. FcRL5 is a prominent target in B cell malignancies and has been implicated as a receptor for immunoglobulin G (IgG). However, the molecular mechanism remained unclear. Here, we demonstrate that human FcRL5, but not its mouse counterpart, is a bona fide IgG-Fc (Fcγ) receptor that uniquely requires the presence of two Fcγ molecules in close proximity to form a robust interaction. Cryo-electron microscopy reveals that FcRL5 optimally engages two Fcγ molecules positioned at a 60° angle, with its D1-D2 domains binding to the first Fcγ molecule, while its D3 domain arches over the second Fcγ. This distinctive binding capability enables FcRL5 to specifically recognize IgG immune complexes (ICs), with the binding strength correlating with IgG concentration in the ICs. In addition, we demonstrate that FcRL5 can internalize the IgG polymer and IC. These results shed light on FcRL5 function and reveal a unique Fcγ-FcγR binding mode governed by avidity.

> **中文摘要：**
> Fc受体在启动免疫球蛋白的效应功能中起关键作用。FcRL5是B细胞恶性肿瘤中的重要靶点，并已被认为是免疫球蛋白G（IgG）的受体。然而，其分子机制尚不清楚。本研究表明，人类FcRL5（而非其小鼠同源物）是真正的IgG-Fc（Fcγ）受体，它独特地需要两种相邻的Fcγ分子共同存在，才能形成稳定的结合。冷冻电子显微镜显示，FcRL5能以约60°的角度最佳地结合两种Fcγ分子，其D1-D2结构域与第一个Fcγ结合，而D3结构域则跨越并接触第二个Fcγ。这种独特的结合能力使FcRL5能够特异性识别IgG免疫复合物（ICs），且结合强度与IC中IgG浓度相关。此外，我们还发现FcRL5能够内吞IgG聚合物和免疫复合物。这些结果揭示了FcRL5的功能，并阐明了一种由多价效应驱动的独特Fcγ-FcγR结合模式。

### 第二部分 AI 大师评价

该研究旨在解析FcRL5与IgG相互作用的分子机制，利用冷冻电镜揭示其独特的双Fcγ结合模式，发现人源FcRL5需两种Fcγ分子协同才能形成稳固复合物。这一发现不仅阐明了FcRL5在B细胞相关疾病中的潜在作用，也揭示了一种全新的受体识别机制。其创新性在于首次观察到双Fcγ协同驱动的受体结合，而局限在于尚需进一步验证其在体内免疫调控中的生理意义。

---

## 24. 免疫抑制性巨噬细胞决定细胞衰老对肿瘤进展的影响

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477861)
**期刊：** Science advances
**PMID：** 41477861
**DOI：** 10.1126/sciadv.adx2988

### 第一部分 原文与翻译

**英文原标题：** Immunosuppressive macrophages determine the effect of cellular senescence on tumor progression.

> **英文摘要：**
> Cells terminally arrested in the cell cycle that exhibit a distinct secretory phenotype are referred to as senescent. These cells play a complex role during tumor progression; they can inhibit or promote tumor growth depending on disease stage. We developed a mouse model that allows monitoring and selective elimination of cells expressing high levels of the cyclin-dependent kinase inhibitor p16 and interleukin-6. These mice, termed SuSe (suicidal senescence), were crossed with the mouse mammary tumor virus-polyomavirus middle T antigen (MMTV-PyMT) model of breast cancer. Functional characterization in SuSe/PyMT mice confirmed that depletion of senescent cells (senolysis) in early and late lesions accelerated and decelerated tumor growth and metastasis, respectively. Tumor acceleration was attributed to expansion of immunosuppressive, protumorigenic macrophages. C-C motif chemokine ligand 2 was identified as an autocrine chemokine essential for their recruitment and maintenance. Depletion of these macrophages reversed the effects of senescent cell clearance, rendering senolysis antitumorigenic even at early stages. Our results suggest that targeting immunosuppressive macrophages can preserve the benefits of senolysis while mitigating adverse effects.

> **中文摘要：**
> 在细胞周期中永久停滞并表现出特异性分泌表型的细胞被称为衰老细胞。这些细胞在肿瘤进展过程中发挥复杂作用；根据疾病阶段不同，它们既能抑制也能促进肿瘤生长。我们建立了一种小鼠模型，可以监测并选择性清除高水平表达细胞周期依赖性激酶抑制因子 p16 和白细胞介素-6 的细胞。这些小鼠被称为 SuSe（自杀性衰老）小鼠，并与乳腺肿瘤小鼠模型 MMTV-PyMT（鼠乳腺肿瘤病毒-多瘤病毒中T抗原）进行杂交。在 SuSe/PyMT 小鼠中的功能特征分析证实，在早期和晚期病灶中清除衰老细胞（衰老细胞溶解，senolysis）分别加速和减缓了肿瘤的生长和转移。肿瘤加速被归因于免疫抑制性、促肿瘤性巨噬细胞的扩增。研究鉴定出 C-C 模式趋化因子配体 2 是这些巨噬细胞募集和维持所必需的自分泌趋化因子。清除这些巨噬细胞可逆转衰老细胞清除的效应，使衰老细胞溶解即便在早期也表现出抗肿瘤作用。我们的结果表明，靶向免疫抑制性巨噬细胞可以在保留衰老细胞溶解益处的同时，减少其不良影响。

### 第二部分 AI 大师评价

本研究基于自杀性衰老小鼠模型深入探讨了细胞衰老在肿瘤进展中的双重作用。作者揭示，衰老细胞的清除在不同阶段对肿瘤的影响相反，而免疫抑制性巨噬细胞是关键调控因子。通过发现 CCL2 在巨噬细胞募集和维持中的核心作用，研究为解释早期衰老细胞清除引发的促肿瘤效应提供了新机制。该工作创新性地联系了衰老免疫微环境与肿瘤命运，提示联合靶向免疫抑制性巨噬细胞可改善衰老细胞清除疗法的安全性与疗效。

---

## 25. 昼夜节律塑造的免疫变异性可预测感染结局

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477859)
**期刊：** Science advances
**PMID：** 41477859
**DOI：** 10.1126/sciadv.adx8112

### 第一部分 原文与翻译

**英文原标题：** Circadian-shaped immune variability predicts infection outcome.

> **英文摘要：**
> Disease risk and severity are influenced by genetics, epigenetics, and environmental factors. However, immune responses vary even among genetically similar or related individuals, shaped by inherited and noninherited factors. Using , we found that pathogen susceptibility can be predicted by preinfection biomarkers. Individuals with high-basal expression of , an infection response gene regulated by the p38 mitogen-activated protein kinase-1 (PMK-1) pathway, were more susceptible to  infection. A genome-wide screen identified the myeloid ecotropic viral integration site-1 (MEIS) homeobox protein UNC-62 as a regulator of  expression, acting through PMK-1 and GATA binding erythroid-like transcription factor (ELT-2). Further analysis revealed that maternal circadian timing shaped offspring immune heterogeneity and inhibition of clock genes eliminated the effects induced by maternal timing. These findings highlight circadian-driven immune variability as a potential adaptive strategy for resilience against infection.

> **中文摘要：**
> 疾病风险和严重程度受遗传、表观遗传及环境因素的影响。然而，即使在遗传背景相似或有亲缘关系的个体之间，免疫反应也存在差异，这种差异由遗传和非遗传因素共同塑造。通过研究，我们发现病原体易感性可通过感染前生物标志物进行预测。那些感染反应基因（受p38丝裂原活化蛋白激酶-1（PMK-1）通路调控）具有高基础表达水平的个体，更易受到感染。全基因组筛选鉴定出髓系生态病毒整合位点-1（MEIS）同源盒蛋白UNC-62，作为上述基因表达的调控因子，通过PMK-1及GATA结合红系样转录因子ELT-2发挥作用。进一步分析显示，母体的昼夜节律时间可影响后代表现出的免疫异质性，而抑制生物钟基因可消除母体时间引起的效应。这些发现强调了昼夜节律驱动的免疫变异性，可能是一种抵御感染的适应性策略。

### 第二部分 AI 大师评价

本研究旨在揭示昼夜节律如何塑造个体的免疫差异性及其对感染结局的预测价值。作者通过多层次实验发现，特定感染反应基因的基础表达水平与宿主的感染易感性密切相关，并识别出UNC-62作为关键调控因子。研究进一步揭示母体昼夜节律可遗传性地影响后代免疫表型，强调了时生物学在免疫调节中的重要作用。其创新之处在于将昼夜节律与免疫异质性联系起来，为个体化感染风险评估提供了新视角，但其在人类模型中的普适性仍需后续验证。

---

## 26. Caspase-2 缺失驱动病理性肝细胞多倍化并增加小鼠与年龄相关的肝细胞癌发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477850)
**期刊：** Science advances
**PMID：** 41477850
**DOI：** 10.1126/sciadv.aeb2571

### 第一部分 原文与翻译

**英文原标题：** Caspase-2 deficiency drives pathogenic liver polyploidy and increases age-associated hepatocellular carcinoma in mice.

> **英文摘要：**
> Hepatocyte polyploidization promotes liver homeostasis by enhancing resistance to cellular stress. Caspase-2, a proapoptotic protease, restricts polyploidization by deleting polyploid and aneuploid cells. While caspase-2 protects against diet-induced hepatic injury, it also acts as a tumor suppressor by controlling genomic instability and oxidative stress. To investigate these roles, we assessed hepatic ploidy dynamics, liver damage, and age-associated tumorigenesis in caspase-2-deficient and catalytically inactive mutant mice. We found that caspase-2 loss promotes early-onset hepatocyte hyperpolyploidy, accompanied by progressive liver inflammation, fibrosis, oxidative liver damage, ferroptosis, and higher incidence of spontaneous hepatocellular carcinoma in aged animals. Proteomic profiling revealed a pathogenic polyploidy-associated signature associated with caspase-2 deficiency and increased predisposition to liver disease and malignancy. These findings establish caspase-2 enzymatic activity as a critical regulator of hepatic genome stability and preventing age-related liver cancer that strongly argue against therapeutic caspase-2 inhibition as a strategy for managing liver injury or cancer risk.

> **中文摘要：**
> 肝细胞多倍化通过增强对细胞应激的抵抗力来促进肝脏的稳态。Caspase-2 作为一种促凋亡蛋白酶，通过清除多倍体和非整倍体细胞来限制多倍化的发生。虽然 caspase-2 能抵御饮食诱导的肝损伤，但它同样通过调控基因组不稳定性和氧化应激发挥抑癌作用。为探究这些功能，我们评估了 caspase-2 基因缺失和催化失活突变小鼠的肝脏倍数体动态、肝损伤及与年龄相关的肿瘤发生。研究结果显示，缺乏 caspase-2 可促进早发性的肝细胞过度多倍化，并伴随进行性肝脏炎症、纤维化、氧化性损伤、铁死亡以及老年动物自发性肝细胞癌的高发。蛋白质组学分析揭示了一种与 caspase-2 缺失及肝病和恶性转化易感性增加相关的病理性多倍化特征。上述发现确立了 caspase-2 的酶学活性是维持肝脏基因组稳定性和预防老年相关肝癌的关键调节因子，并强烈反对以抑制 caspase-2 活性作为治疗肝损伤或癌症风险管理的策略。

### 第二部分 AI 大师评价

该研究通过在缺失及催化失活突变小鼠中系统评估肝脏倍数体动态与肿瘤发生，揭示了 caspase-2 在维持肝脏基因组稳定和防止与年龄相关的肝癌中的关键作用。研究发现缺乏 caspase-2 会导致病理性多倍化、氧化损伤和肝癌易感性增加，提示其酶学活性在肝脏稳态中不可或缺。该工作通过结合分子遗传与蛋白质组学分析，创新性地阐明了多倍体失控与肿瘤发生之间的机制关联，但其临床相关性仍需在人体模型中进一步验证。

---

## 27. TFEB通过SQSTM1在饥饿状态下协调自噬体生成与核糖体自噬。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477847)
**期刊：** Science advances
**PMID：** 41477847
**DOI：** 10.1126/sciadv.aea9302

### 第一部分 原文与翻译

**英文原标题：** TFEB coordinates autophagosome biogenesis and ribophagy during starvation via SQSTM1.

> **英文摘要：**
> (Macro)autophagy is a conserved cellular degradation pathway that delivers substrates to lysosomes via autophagosomes. Among various physiological stimuli, nutrient starvation is the most potent inducer of autophagy. In response to starvation, transcription factor EB (TFEB) is activated and up-regulates a broad set of autophagy-related genes. However, the mechanisms by which TFEB promotes autophagosome biogenesis remain incompletely understood. Here, we demonstrate that TFEB-mediated transcriptional induction of  (SQSTM1; p62) triggers the formation of SQSTM1-positive bodies that recruit essential autophagy factors, thereby initiating autophagosome biogenesis. Genetic disruption of TFEB-dependent SQSTM1 regulation markedly impairs starvation-induced autophagy, underscoring the critical role of the TFEB-SQSTM1 axis in the autophagic response to nutrient stress. Furthermore, we show that these SQSTM1 bodies contain ubiquitinated ribosomal proteins and that TFEB promotes ribosomal protein ubiquitination by inducing the E3 ubiquitin ligase ZNF598. Collectively, our findings uncover a transcriptionally coordinated mechanism that regulates both autophagosome biogenesis and substrate ubiquitination, facilitating efficient cargo clearance during starvation-induced autophagy.

> **中文摘要：**
> （巨）自噬是一种保守的细胞降解途径，通过自噬体将底物运送至溶酶体。在各种生理刺激中，营养饥饿是最强的自噬诱导因素。为响应饥饿，转录因子EB（TFEB）被激活，并上调一系列与自噬相关的基因。然而，TFEB促进自噬体生成的具体机制尚未完全阐明。在本研究中，我们证明了由TFEB介导的（SQSTM1；p62）转录诱导可触发SQSTM1阳性小体的形成，这些小体能够招募关键的自噬因子，从而启动自噬体的生成。干扰TFEB依赖的SQSTM1调控会显著损害饥饿诱导的自噬，强调了TFEB-SQSTM1轴在营养应激下自噬反应中的关键作用。此外，我们发现，这些SQSTM1小体包含泛素化的核糖体蛋白，并且TFEB通过诱导E3泛素连接酶ZNF598促进核糖体蛋白的泛素化。综上，我们的研究揭示了一种协调性转录调控机制，该机制同时调节自噬体生物发生和底物泛素化，从而促进饥饿诱导自噬过程中高效的货物清除。

### 第二部分 AI 大师评价

本研究聚焦于在营养饥饿条件下，TFEB如何通过SQSTM1协调自噬体的生成和核糖体自噬。作者通过遗传和分子机制研究阐明，TFEB不仅上调与自噬相关基因，还通过诱导SQSTM1和E3泛素连接酶ZNF598，协调底物泛素化及自噬体形成。研究揭示了TFEB-SQSTM1轴在饥饿应激下维持细胞稳态的核心作用，创新性地连接了转录调控、自噬体生成及核糖体降解，深化了对自噬调控网络的理解。其局限性在于主要基于细胞水平研究，仍需在动物模型和病理情境中进一步验证。

---

## 28. 胆固醇外排蛋白ABCA1支持髓系免疫细胞的抗癌功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477845)
**期刊：** Science advances
**PMID：** 41477845
**DOI：** 10.1126/sciadv.adx5490

### 第一部分 原文与翻译

**英文原标题：** Cholesterol efflux protein, ABCA1, supports anticancer functions of myeloid immune cells.

> **英文摘要：**
> Breast and other solid tumors respond poorly to immune therapy. Myeloid cells (MCs) such as macrophages contribute to resistance. Established clinical evidence links cholesterol to cancer outcomes, with MC function being regulated by cholesterol metabolism. We screened MC-expressed regulators of cholesterol homeostasis linked to survival and identified the cholesterol efflux protein ABCA1. ABCA1 activity increases anticancer functions of macrophages: enhancing tumor infiltration, decreasing angiogenic potential, reducing efferocytosis, and improving support of CD8+ T cell activity. Mechanistically, different AKT isoforms are involved, through both PI3K-dependent and PI3K-independent mechanisms. Highlighting the clinical relevance of our findings are correlations between ABCA1 in macrophages and angiogenic potential, , and CD8 T cell abundance and activity. The culmination of these activities was demonstrated through increased tumor growth and metastasis in mice lacking MC-expressed ABCA1. Tumors grown in these mice were also more resistant to immune therapy. Therefore, modulating ABCA1 activity within MCs may represent a previously unidentified approach to immune therapy.

> **中文摘要：**
> 乳腺癌及其他实体瘤对免疫治疗的反应较差。包括巨噬细胞在内的髓系细胞（MCs）在耐受性中起作用。既有的临床证据显示胆固醇与癌症结局相关，而髓系细胞的功能受胆固醇代谢调控。我们筛选了与生存相关的、由髓系细胞表达的胆固醇稳态调控因子，并确定了胆固醇外排蛋白ABCA1。ABCA1的活性可增强巨噬细胞的抗癌功能：促进肿瘤浸润，降低血管生成潜能，减少凋亡细胞吞噬（efferocytosis），并增强对CD8+ T细胞活性的支持。从机制上看，不同的AKT同工型通过依赖PI3K及非依赖PI3K的机制共同参与其中。具有临床相关性的是，巨噬细胞中ABCA1表达与血管生成潜能、CD8+ T细胞数量及活性之间存在相关性。这些作用的综合结果表现为缺乏髓系细胞表达ABCA1的小鼠中肿瘤生长和转移增加。在这些小鼠中生长的肿瘤对免疫治疗也更具耐受性。因此，调控髓系细胞内ABCA1活性可能代表一种此前未被识别的免疫治疗策略。

### 第二部分 AI 大师评价

该研究旨在阐明胆固醇外排蛋白ABCA1在髓系免疫细胞中的抗癌作用。研究通过筛选与胆固醇稳态和平衡相关的调控因子，发现ABCA1可增强巨噬细胞的免疫功能并改善T细胞反应。机制分析显示，不同AKT同源物通过多途径介导ABCA1的作用，揭示其在肿瘤免疫调控中的复杂网络。该发现为抗癌免疫治疗提供了新的代谢靶点，但仍需进一步确定人类肿瘤中ABCA1调控的时空特异性及潜在副作用。

---

## 29. 系统性诱导训练性免疫克服实体瘤的免疫抑制性微环境

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477842)
**期刊：** Science advances
**PMID：** 41477842
**DOI：** 10.1126/sciadv.adu0292

### 第一部分 原文与翻译

**英文原标题：** Systemically inducing trained immunity overcomes solid tumors' immunosuppressive microenvironment.

> **英文摘要：**
> Hematopoietic bone marrow progenitors are increasingly implicated as an origin of immunosuppression in cancer. We have previously shown that trained immunity induction using nanomedicine potentiates checkpoint blockade therapy. Here, we studied how this approach's induction of trained immunity systemically overcomes the immunosuppressive tumor microenvironment. We found changes in the tumor microenvironment to mirror functional changes in the hematopoietic system in a melanoma mouse model. Single cell sequencing methods disclosed a shift in the tumor-associated macrophage population from immunosuppressive to antitumorigenic. Uniquely, a trained immunity and checkpoint blockade combination therapy mobilized natural killer cells which, in conjunction with the functional changes in the myeloid cell compartment, effectively activated T cells. Last, we established the effectiveness of our approach in mouse models of breast, lung, and pancreatic cancer. Collectively, our data show that the systemic induction of trained immunity rebalances the immune system for effective checkpoint blockade therapy.

> **中文摘要：**
> 造血骨髓前体细胞越来越多地被认为是癌症免疫抑制的起源。我们此前已显示，利用纳米医学诱导训练性免疫可增强检查点阻断治疗效果。在本研究中，我们探讨了这一方法在全身范围内诱导训练性免疫如何克服肿瘤的免疫抑制性微环境。我们发现，在黑色素瘤小鼠模型中，肿瘤微环境的变化反映出造血系统的功能性改变。单细胞测序结果显示，肿瘤相关巨噬细胞群体从免疫抑制型向抗肿瘤型转变。特别地，训练性免疫与检查点阻断的联合治疗可动员自然杀伤细胞，与髓系细胞群功能性改变协同，有效激活T细胞。最后，我们在乳腺癌、肺癌及胰腺癌的小鼠模型中验证了该方法的有效性。总体而言，我们的数据表明，全身诱导训练性免疫能够重新平衡免疫系统，从而增强检查点阻断治疗的效果。

### 第二部分 AI 大师评价

该研究旨在通过系统性诱导训练性免疫来改善肿瘤免疫抑制性微环境。作者利用纳米医学手段结合检查点阻断治疗，在黑色素瘤及多种实体瘤模型中验证了该策略的有效性。研究揭示训练性免疫使肿瘤相关巨噬细胞由免疫抑制型向抗肿瘤型转化，并动员自然杀伤细胞与T细胞协同发挥作用。这一成果为利用先天免疫重塑提升免疫疗法提供了新思路，但仍需进一步评估其在人类肿瘤中的安全性与可转化性。

---

## 30. 全基因组关联研究揭示人类视网膜色素沉着的遗传结构与进化特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477839)
**期刊：** Science advances
**PMID：** 41477839
**DOI：** 10.1126/sciadv.adw7768

### 第一部分 原文与翻译

**英文原标题：** Genome-wide association study reveals genetic architecture and evolution of human retinal pigmentation.

> **英文摘要：**
> Pigmentation varies widely across humans and is shaped by melanin quantity, type, and spatial distribution. Retinal pigmentation protects against light-induced damage, yet its genetic and evolutionary bases remain unclear. We developed a deep learning framework (DeepGRP) to quantify retinal pigmentation from high-resolution fundus images and conducted a genome-wide association study (GWAS), identifying 42 signals, including 26 previously unidentified loci, with single-nucleotide polymorphism-based heritability of 21.4%. Single-nucleus assay for transposase-accessible chromatin by sequencing and RNA sequencing of human fetal retinal tissues revealed key cellular contributors, including retinal pigment epithelium and photoreceptor cells. Among candidate genes,  emerged as a previously unrecognized regulator of melanogenesis. Evidence of polygenic adaptation in Europeans suggests selection driven by snow-reflected light at high latitudes. A polygenic risk score for retinal pigmentation correlated with a 4.8-fold higher risk of myopia and a 1.5-fold lower risk of skin cancer. These findings demonstrate the power of deep learning for large-scale ocular phenotyping and reveal insights into the genetic and evolutionary architecture of retinal pigmentation.

> **中文摘要：**
> 人类的色素沉着差异显著，其形成受到黑色素数量、类型及空间分布的影响。视网膜色素沉着可防止光照诱导的损伤，但其遗传与进化基础尚不明确。我们开发了一种深度学习框架（DeepGRP），可从高分辨率眼底图像中量化视网膜色素沉着，并进行了全基因组关联研究（GWAS），共识别出42个信号，其中包括26个此前未发现的位点，其基于单核苷酸多态性的遗传率为21.4%。对人类胎儿视网膜组织进行的单核可及染色质测序分析和RNA测序揭示了主要的细胞贡献者，包括视网膜色素上皮和感光细胞。在候选基因中，出现了一个此前未被认知的黑色素生成调控因子。在欧洲人群中发现的多基因适应证据表明，可能存在受高纬地区雪面反射光驱动的自然选择。视网膜色素沉着的多基因风险评分与近视风险增加4.8倍以及皮肤癌风险降低1.5倍相关。这些发现展示了深度学习在大规模眼部表型分析中的强大能力，并揭示了视网膜色素沉着的遗传及进化结构的全新见解。

### 第二部分 AI 大师评价

本研究通过结合深度学习与全基因组关联分析，系统探究了人类视网膜色素沉着的遗传结构及其进化机制。研究不仅识别出多个新的遗传位点，还揭示了关键细胞类型和基因在黑色素生成中的作用，并发现了与地理适应相关的选择信号。通过多基因风险评分关联分析，进一步揭示了色素沉着与近视及皮肤癌风险之间的潜在联系。此研究在利用人工智能进行复杂眼部表型解析方面具有创新性，但后续仍需在不同人群中验证其遗传效应的普适性。

---

## 31. 基于机器学习的 DNA 折纸标签单分子癌症诊断方法

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477820)
**期刊：** Science advances
**PMID：** 41477820
**DOI：** 10.1126/sciadv.adz8174

### 第一部分 原文与翻译

**英文原标题：** Machine learning-powered single-molecule cancer diagnosis using DNA origami tags.

> **英文摘要：**
> Single-molecule detection (SMD) holds considerable promise in biomedical research. Although atomic force microscopy (AFM) provides an important technique with nanoscale resolution for SMD, its broader application is limited by labeling challenges and slow data processing. Here, we present a machine learning (ML)-powered strategy combining AFM and DNA nanotags for SMD and cancer diagnosis. Nickases are applied to create specific single-strand breaks in target DNA, allowing insertion of exogenous DNA to attach shape-distinct nanotags for AFM imaging. A YOLOv5l algorithm is adopted to automatically recognize target objects in AFM images, which can classify 370 structures in 1.21 seconds with 98% accuracy. The proof of concept of this strategy is confirmed by identifying nickase-edited sites on both linear and circular DNA. Its practical applicability is demonstrated by detecting KRAS Gly12Arg (G12R) and p53 Arg175His (R175H) mutations in samples from patients with pancreatic and colorectal cancer, with accuracy rivaling Sanger sequencing and quantitative polymerase chain reaction, opening avenues for SMD.

> **中文摘要：**
> 单分子检测（SMD）在生物医学研究中具有巨大的应用潜力。虽然原子力显微镜（AFM）提供了一种具备纳米级分辨率的重要 SMD 技术，但其广泛应用受限于标记困难和数据处理速度缓慢。本文提出了一种结合 AFM 与 DNA 纳米标签、由机器学习（ML）驱动的 SMD 与癌症诊断策略。通过使用切口酶在靶 DNA 上产生特定的单链断裂，从而插入外源 DNA 以连接形态可区分的纳米标签，用于 AFM 成像。采用 YOLOv5l 算法自动识别 AFM 图像中的目标对象，能够在 1.21 秒内以 98% 的准确率分类 370 种结构。该策略的概念验证通过在直线型及环状 DNA 上识别切口酶编辑位点得以证实。其实际应用性通过检测胰腺癌和结直肠癌患者样本中的 KRAS Gly12Arg（G12R）和 p53 Arg175His（R175H）突变得到验证，其准确度可与桑格测序和定量聚合酶链式反应相媲美，为单分子检测开辟了新的途径。

### 第二部分 AI 大师评价

该研究提出了一种融合原子力显微镜与 DNA 折纸标签、由机器学习算法驱动的单分子癌症诊断方法，旨在克服传统单分子检测中的标记和数据处理瓶颈。研究利用切口酶进行精确的 DNA 标记，并采用 YOLOv5l 模型实现高效自动识别，显著提升了检测速度与准确率。通过验证 KRAS 与 p53 致癌突变的检测，展示了其实用价值。该方法创新性地结合了纳米技术与人工智能，为精密分子诊断提供了新的方向，但未来仍需评估其在更复杂临床样本中的稳定性与可扩展性。

---

## 32. 一种特异于SWI/SNF复合物的免疫球蛋白样结构域——SWIFT，是转录因子结合的平台。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477818)
**期刊：** Science (New York, N.Y.)
**PMID：** 41477818
**DOI：** 10.1126/science.aeb3627

### 第一部分 原文与翻译

**英文原标题：** A SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding platform.

> **英文摘要：**
> Mammalian SWI/SNF chromatin remodeling complexes modulate DNA accessibility and gene expression; however, their genomic targeting mechanisms remain incompletely understood. Here, we identify SWIFT (SWI/SNF Ig-fold for transcription factor interactions), a conserved transcription factor (TF) binding platform on the SMARCD subunits. SWIFT is necessary and sufficient for direct engagement with the transactivation domain of PU.1. A single amino acid mutation disrupts PU.1-mSWI/SNF binding, impairs complex targeting, and attenuates oncogenic transcription and proliferation in PU.1-dependent cancer cells. Dominant expression of the SWIFT domain in isolation sequesters TFs from mSWI/SNF and poisons TF-addicted cancer cells. Finally, TFs across diverse families interact with SMARCD paralog-specific SWIFT domains. These results define a major mechanism of cell type- and disease-specific mSWI/SNF chromatin targeting and inform approaches toward therapeutic modulation.

> **中文摘要：**
> 哺乳动物SWI/SNF染色质重塑复合物调控DNA可及性和基因表达；然而，其基因组定位机制仍未被完全阐明。本文鉴定出SWIFT（SWI/SNF Ig折叠结构用于转录因子相互作用），这是位于SMARCD亚基上的一个保守的转录因子（TF）结合平台。SWIFT对于与PU.1的转录激活结构域直接结合既是必要的也是充分的。单个氨基酸突变会破坏PU.1与mSWI/SNF的结合，削弱复合物的靶向能力，并降低PU.1依赖型癌细胞中的致癌性转录和增殖。单独过表达SWIFT结构域可将转录因子从mSWI/SNF中分离出来，从而毒害依赖转录因子的癌细胞。最后，各种家族的转录因子均与SMARCD旁系同源物特异的SWIFT结构域相互作用。这些结果揭示了细胞类型和疾病特异性mSWI/SNF染色质靶向的主要机制，并为治疗性调控策略提供了新的思路。

### 第二部分 AI 大师评价

本研究通过结构与分子互作分析，揭示了SWI/SNF复合物中一种新型免疫球蛋白样结构域SWIFT在转录因子识别中的关键作用。研究团队发现SWIFT可直接结合转录因子PU.1，其结构完整性对复合物靶向和致癌转录调控至关重要。功能验证表明SWIFT的突变和异常表达显著影响依赖TF的癌细胞生长，提示其可能作为新的治疗靶点。该工作首次定义了SWI/SNF复合物的泛转录因子结合平台，拓展了对染色质重塑复合体特异性靶向机制的理解，但其在多种肿瘤类型中的普适性仍需进一步研究。

---

## 33. 处于活性氧与困境之间：端粒损伤作为T细胞衰竭的驱动因素

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41115213)
**期刊：** Cancer research
**PMID：** 41115213
**DOI：** 10.1158/0008-5472.CAN-25-4716

### 第一部分 原文与翻译

**英文原标题：** Between ROS and a Hard Place: Telomere Damage as a Driver of T-cell Exhaustion.

> **英文摘要：**
> In recent years, the accumulation of mitochondrial reactive oxygen species (ROS) has been shown to limit the proliferative capacity and intratumoral persistence of CD8+ T cells, but the molecular mechanisms by which ROS produces functional defects in exhausted CD8+ T cells remain incompletely understood. Using a series of elegant genetic tools, Rivadeneira and colleagues demonstrate that the accumulation of mitochondrial ROS is sufficient to directly compromise telomere integrity. The authors induced singlet oxygen within specific subcellular compartments in T cells, achieving precise temporal and spatial control over ROS production. Genetically driven mitochondrial ROS accumulation reproduced hallmarks of intratumoral T-cell dysfunction while also producing marked telomere fragility. Consistent with these findings, tumor-infiltrating CD8+ T cells from patients with melanoma and head and neck cancers exhibited substantial accumulation of DNA damage at telomeres compared with healthy donor or autologous peripheral T cells. Moreover, restricting ROS generation specifically to telomeres was sufficient to reproduce T-cell dysfunction, whereas targeting the antioxidant enzyme glutathione peroxidase 1 to telomeres reduced DNA damage and enhanced T-cell effector functions, leading to improved tumor control. These findings reveal telomeres as key mediators of redox stress-driven T-cell dysfunction and suggest that interventions aimed at protecting chromosome ends may represent a novel strategy to enhance antitumor immunity.

> **中文摘要：**
> 近年来，线粒体活性氧（ROS）的积累已被证实会限制CD8+ T细胞的增殖能力及其在肿瘤内的持续存在，但ROS导致衰竭CD8+ T细胞功能缺陷的分子机制仍未完全明确。Rivadeneira及其同事利用一系列精巧的遗传学工具，证明线粒体ROS的积累足以直接损害端粒的完整性。研究者在T细胞特定亚细胞区室内诱导单重态氧，从而实现对ROS生成的时间和空间的精确控制。遗传驱动的线粒体ROS积累不仅再现了肿瘤内T细胞功能障碍的特征，还导致显著的端粒脆弱性。与这些发现一致，来自黑色素瘤以及头颈癌患者的肿瘤浸润性CD8+ T细胞，相较于健康供者或自体外周T细胞，显示出端粒处DNA损伤的大量积累。此外，将ROS的生成限制在端粒区域足以再现T细胞功能障碍，而将抗氧化酶谷胱甘肽过氧化物酶1（glutathione peroxidase 1）靶向至端粒则可减少DNA损伤并增强T细胞效应功能，从而改善肿瘤控制。这些结果揭示了端粒作为氧化还原应激驱动的T细胞功能障碍的关键介导者的作用，并提示针对染色体末端保护的干预可能成为增强抗肿瘤免疫的新策略。

### 第二部分 AI 大师评价

本研究揭示了线粒体活性氧通过破坏端粒完整性直接推动CD8+ T细胞衰竭，为红氧应激与免疫功能障碍之间建立了关键联系。作者利用精确的遗传和光控技术实现细胞内ROS的时空调控，系统性地证明了端粒损伤在T细胞功能丧失中的因果作用。通过靶向抗氧化酶至端粒恢复T细胞功能并改善肿瘤控制，显示出潜在的临床转化价值。研究创新性在于将端粒稳态界定为红氧应激驱动免疫抑制的核心节点，但仍需进一步探索其在不同肿瘤类型及临床环境中的适用性。

---

## 34. PRT3789：首个选择性降解SMARCA2并在SMARCA4突变癌症中诱导合成致死的早期人体用药。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40991405)
**期刊：** Cancer research
**PMID：** 40991405
**DOI：** 10.1158/0008-5472.CAN-25-1141

### 第一部分 原文与翻译

**英文原标题：** PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.

> **英文摘要：**
> UNLABELLED: SMARCA2 and SMARCA4 are the core catalytic subunits of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex. Approximately 10% of patients with non-small cell lung cancer patients harbor SMARCA4 mutations, resulting in protein loss or loss-of-function alterations. These SMARCA4-deficient cancers are highly dependent on SMARCA2 for proliferation, growth, and survival, making SMARCA2 a promising synthetic lethal target. In this study, we developed and characterized PRT3789, a clinical-stage SMARCA2-selective targeted protein degrader. It induced polyubiquitination at lysine residues unique to SMARCA2 through stable ternary complex formation with the Von Hippel-Lindau E3 ligase. The selectivity was driven by interactions with an extended loop unique to SMARCA2, as revealed by structure-based analyses. PRT3789 promoted selective degradation of SMARCA2 while sparing its highly homologous paralog, SMARCA4. In SMARCA4-deficient models, SMARCA2 degradation disrupted SWI/SNF complex integrity by inducing dissociation of multiple subunits, leading to downstream transcriptional reprogramming. PRT3789 induced robust tumor growth inhibition and regression in SMARCA4-deficient models, both as monotherapy and in combination with targeted therapies or chemotherapies. In contrast, SMARCA4 wild-type models exhibited minimal response despite confirmed SMARCA2 degradation, consistent with SMARCA4 sparing and preserved SWI/SNF complex integrity. In clinical settings, PRT3789 reduced SMARCA2 protein levels in peripheral blood mononuclear cells from patients with SMARCA4-mutated cancers. Initial signs of clinical activity have been observed, including RECIST-confirmed partial responses. Together, these findings demonstrate the selective targeting of SMARCA2 and the potential for a favorable therapeutic index with PRT3789. Phase I/II clinical trials with PRT3789 are ongoing in biomarker-selected patients with SMARCA4-mutated solid tumors. SIGNIFICANCE: PRT3789 selectively degrades SMARCA2 and demonstrates activity in SMARCA4-deficient cancers while sparing wild-type models, validating paralog synthetic lethality, and supporting clinical development in SMARCA4-mutated patients, a population with high unmet need.

> **中文摘要：**
> 未标注：SMARCA2和SMARCA4是SWI/SNF染色质重塑复合物的核心催化亚基。约有10%的非小细胞肺癌患者携带SMARCA4突变，导致蛋白缺失或失功能改变。这类SMARCA4缺陷型癌症在增殖、生长和生存上高度依赖SMARCA2，使SMARCA2成为一种有前景的合成致死靶点。在本研究中，我们开发并表征了一种临床阶段的SMARCA2选择性靶向蛋白降解剂——PRT3789。通过与Von Hippel-Lindau E3连接酶形成稳定的三元复合物，它在SMARCA2特异性赖氨酸残基上诱导多泛素化。基于结构的分析显示，该选择性来源于其与SMARCA2特有延伸环的相互作用。PRT3789可促进SMARCA2的选择性降解，而保留其高度同源的旁系基因SMARCA4。在SMARCA4缺陷模型中，SMARCA2的降解通过诱导多个亚基解离破坏SWI/SNF复合物的完整性，从而引发下游的转录重编程。PRT3789在SMARCA4缺陷模型中，无论单药使用还是与靶向治疗或化疗联合使用，都可诱导显著的肿瘤生长抑制与回归。相对地，SMARCA4野生型模型即使确认SMARCA2被降解，也仅出现极小反应，与SMARCA4被保留及SWI/SNF复合物结构完整性维持一致。在临床应用中，PRT3789可降低SMARCA4突变癌症患者外周血单核细胞中的SMARCA2蛋白水平，且已观察到初步临床活性迹象，包括经RECIST标准确认的部分缓解。总体而言，这些结果证明了SMARCA2的选择性靶向及PRT3789潜在的良好治疗指数。目前，PRT3789的I/II期临床试验正在生物标志物筛选的SMARCA4突变实体瘤患者中进行。
> 研究意义：PRT3789选择性降解SMARCA2，并在SMARCA4缺陷癌症中展现活性，同时保留野生型模型，从而验证了旁系基因合成致死概念，并支持其在SMARCA4突变患者中开展临床开发，这是一类临床未满足需求较高的人群。

### 第二部分 AI 大师评价

本研究系统阐述了PRT3789作为首个临床阶段SMARCA2选择性降解剂的发现与验证过程。研究团队揭示了其基于结构特异性相互作用实现的高选择性及其在SMARCA4缺陷癌模型中的强效抗瘤活性，验证了SMARCA2与SMARCA4之间的旁系合成致死机制。该药物在临床前及早期临床阶段均显示积极信号，提示其潜在的治疗价值。创新性在于首次实现特异靶向SMARCA2的降解并在SMARCA4突变癌中获得实质性疗效，但仍需更多临床数据验证其安全性与疗效持久性。

---

## 35. TYK2促进结直肠癌肝转移的免疫监视

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40991399)
**期刊：** Cancer research
**PMID：** 40991399
**DOI：** 10.1158/0008-5472.CAN-24-4224

### 第一部分 原文与翻译

**英文原标题：** TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis.

> **英文摘要：**
> UNLABELLED: Colorectal cancer liver metastasis (CRLM) is a major clinical problem. The regulators of immunosurveillance of CRLM could hold potential for developing therapeutic strategies to prevent or treat metastasis. In this study, using a murine colorectal cancer organoid-based transplantation model, we identified TYK2 as a key factor controlling CRLM. Evaluation of the effects of Tyk2 deletion in different subsets of immune cells and in colorectal cancer cells demonstrated that TYK2 was not required in cancer cells, macrophages, NK cells, T cells, or Kupffer cells. Instead, TYK2 controlled CRLM via a dendritic cell-dependent mechanism that relied on MHC-I-mediated cross-presentation of antigens to CD8+ T cells. Analysis of single-cell RNA sequencing data from primary colorectal cancer and CRLM revealed that TYK2 was predominantly expressed in a dendritic cell population destined to present antigens in tumor-draining lymph nodes. Treatment with the TYK2 inhibitor deucravacitinib, which is approved by the FDA for treating plaque psoriasis and is under clinical investigation for other autoimmune diseases, promoted CRLM. Together, these data demonstrate that TYK2 controls CRLM immunosurveillance, which should be carefully considered when treating patients with TYK2 inhibitors.
> 
> SIGNIFICANCE: TYK2 restricts the metastasis of colorectal tumors to the liver by supporting dendritic cell-dependent induction of antitumor CD8+ T cells, which could impact the use of TYK2 inhibitors in patients.

> **中文摘要：**
> 未加标签：结直肠癌肝转移（CRLM）是一个主要的临床问题。CRLM免疫监视的调控因子可能为开发预防或治疗转移的治疗策略提供潜在方向。在本研究中，利用小鼠结直肠癌类器官移植模型，我们鉴定出TYK2是控制CRLM的关键因子。对不同免疫细胞亚群及结直肠癌细胞中Tyk2缺失效应的评估表明，TYK2在癌细胞、巨噬细胞、自然杀伤细胞、T细胞或Kupffer细胞中并非必需。相反，TYK2通过依赖树突状细胞的机制来控制CRLM，该机制依靠MHC-I介导的抗原交叉呈递以激活CD8+ T细胞。对原发性结直肠癌及CRLM的单细胞RNA测序数据分析显示，TYK2主要表达于一种注定在肿瘤引流淋巴结中呈递抗原的树突状细胞群中。使用TYK2抑制剂Deucravacitinib（已获FDA批准用于治疗斑块型银屑病，并正在其他自身免疫病中进行临床研究）处理可促进CRLM的发生。综上所述，这些数据表明TYK2调控CRLM的免疫监视，在治疗患者时应用TYK2抑制剂应谨慎考虑。
> 
> 意义：TYK2通过支持树突状细胞依赖的抗肿瘤CD8+ T细胞诱导，限制结直肠肿瘤向肝脏转移，这一作用可能影响TYK2抑制剂在患者中的应用。

### 第二部分 AI 大师评价

该研究揭示了TYK2在结直肠癌肝转移免疫监视中的核心作用。研究者利用小鼠类器官移植模型及单细胞转录组分析，发现TYK2主要通过树突状细胞依赖的抗原交叉呈递途径调控CD8+ T细胞介导的抗肿瘤免疫。进一步实验显示，TYK2抑制剂Deucravacitinib可能促进肝转移发生。该研究创新性地阐明了TYK2在肿瘤免疫微环境中的特定细胞功能，对临床使用TYK2抑制剂提出了重要警示，但仍需更多临床研究验证其在人体中的相应机制。

---

## 36. 细胞外囊泡封装的 miR-99a 重编程成纤维细胞，形成促进结直肠癌转移的炎症微环境

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40991395)
**期刊：** Cancer research
**PMID：** 40991395
**DOI：** 10.1158/0008-5472.CAN-25-0663

### 第一部分 原文与翻译

**英文原标题：** Extracellular Vesicle-Packaged miR-99a Reprograms Fibroblasts to Create an Inflammatory Niche That Drives Colorectal Cancer Metastasis.

> **英文摘要：**
> UNLABELLED: Inflammation and epithelial-to-mesenchymal transition are hallmarks of cancer progression. A better understanding of the mechanisms driving these processes could help uncover strategies to treat and prevent metastasis. In this study, we found that extracellular vesicle (EV)-mediated cross-talk between colorectal cancer cells and fibroblasts facilitates inflammation and promotes metastasis. Fibroblasts were highly activated in primary tumors from patients with colorectal cancer with metastatic disease, and EVs secreted from highly metastatic colorectal cancer cells promoted fibroblast activation. Mechanistically, EV-packaged miR-99a-5p (EV-miR-99a) specifically targeted NLRP2 mRNA in fibroblasts and activated the proinflammatory NFκB signaling pathway, thereby converting normal fibroblasts into cancer-associated fibroblasts (CAF). EV-miR-99a-activated CAFs enhanced the migratory capacity of colorectal cancer cells by secreting CCL7, which potently induced epithelial-to-mesenchymal transition by increasing the expression of multiple E-cadherin repressors via the CCR5-mTOR-p70S6K pathway. Expression of miR-99a in colorectal cancer cells was upregulated by TGFβ1 secreted from CAFs in an NFκB-dependent manner, forming an miR-99a/TGFβ1 regulatory circuit. The communication between colorectal cancer cells and fibroblasts engendered a proinflammatory niche that facilitated metastasis, which could be abolished by treatment with the p70S6K inhibitor LY2584702. Clinically, EV-miR-99a levels in the plasma correlated with the metastatic status of patients with colorectal cancer. Together, these findings highlight the metastasis-promoting function of an inflammatory fibroblast niche induced by cancer cell-derived EVs and provide potential targets for the prediction and management of colorectal cancer metastasis.
> 
> SIGNIFICANCE: Extracellular vesicle-mediated cross-talk between colorectal cancer cells and fibroblasts orchestrates a proinflammatory niche that induces and facilitates metastasis and provides potential targets for disease prediction and therapeutic intervention.

> **中文摘要：**
> 未加标签：炎症及上皮-间质转化是肿瘤进展的标志。更深入了解驱动这些过程的机制，有助于发现治疗和预防转移的策略。在本研究中，我们发现结直肠癌细胞与成纤维细胞间通过细胞外囊泡（EV）介导的相互作用促进炎症并增强转移。来自具有转移病灶的结直肠癌患者的原发肿瘤中，成纤维细胞表现出高度活化，而来自高转移性结直肠癌细胞的EV可进一步促进其活化。从机制上讲，封装于EV中的miR-99a-5p（EV-miR-99a）可特异性靶向成纤维细胞内的NLRP2 mRNA，并激活促炎性的NFκB信号通路，从而将正常成纤维细胞转化为癌相关成纤维细胞（CAF）。经EV-miR-99a激活的CAF通过分泌CCL7增强结直肠癌细胞的迁移能力。CCL7通过CCR5-mTOR-p70S6K通路上调多种E-钙黏蛋白抑制因子的表达，从而显著诱导上皮-间质转化。结直肠癌细胞中miR-99a的表达受CAF分泌的TGFβ1在NFκB依赖性方式下上调，形成miR-99a/TGFβ1调控回路。结直肠癌细胞与成纤维细胞之间的交流导致形成促炎性生态位，从而促进肿瘤转移，而这种效应可被p70S6K抑制剂LY2584702阻断。在临床上，血浆中EV-miR-99a水平与结直肠癌患者的转移状态呈正相关。综上，这些发现揭示癌细胞来源EV诱导的炎症性成纤维细胞生态位在促进转移中的作用，并提供用于结直肠癌转移预测与干预的潜在靶点。
> 
> 研究意义：通过细胞外囊泡介导的结直肠癌细胞与成纤维细胞间的相互作用共同构建了一个促炎性生态位，该生态位诱导并促进转移，并为疾病预测与治疗干预提供潜在靶标。

### 第二部分 AI 大师评价

该研究揭示了结直肠癌细胞通过细胞外囊泡传递miR-99a-5p，重编程成纤维细胞形成促炎微环境的分子机制。研究结合细胞实验、机制解析及临床样本验证，系统阐述了EV-miR-99a/NLRP2/NFκB轴在癌—基质互作中的关键作用。发现的miR-99a/TGFβ1正反馈环路进一步说明了癌细胞与CAF之间的动态通信。该研究创新性地揭示了炎症性成纤维细胞生态位促进转移的机制，并提出p70S6K抑制剂作为潜在干预靶点，但仍需进一步验证其临床应用的有效性与安全性。

---

## 37. 大型患者来源细胞系队列的药物基因组学特征分析揭示胸膜间皮瘤的治疗策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40991303)
**期刊：** Cancer research
**PMID：** 40991303
**DOI：** 10.1158/0008-5472.CAN-24-3822

### 第一部分 原文与翻译

**英文原标题：** Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma.

> **英文摘要：**
> UNLABELLED: Pleural mesothelioma (PM) urgently requires effective treatments. This study aimed to identify potential therapies using a drug repurposing strategy in the context of the molecular heterogeneity of PM. We performed a multiomics study of a large cohort of patient-derived primary PM cell lines (n = 58) and conducted a multistep pharmacologic study starting with a large-scale drug screen with 1,327 compounds using 11 cell lines to select drugs of interest. Integrated multiomics analysis demonstrated that the molecular landscape of the cell line cohort recapitulates the main findings in tumors and revealed important features of PM. Large-scale drug screening identified 233 active compounds belonging to recurrent therapeutic classes. Subsequent validation of 35 compounds highlighted a subset of 12 compounds performing better than standard chemotherapy, including entinostat and fluvastatin, with therapeutic activity related to molecular sarcomatoid phenotype, BAP1 mutation, and YAP/TAZ activity. Importantly, both compounds displayed the same efficacy in 2D and 3D culture models, and a single treatment with entinostat improved survival in an immunocompetent mouse model compared with fluvastatin and standard cisplatin-pemetrexed chemotherapy, which showed similar antitumor effects. Strikingly, entinostat improved the efficacy of immunotherapy based on anti-PD-1 antibody. Combination of entinostat with anti-PD-1 even eradicated tumors in several mice and immunized them against retransplantation of tumor cells. Overall, the drug sensitivity data provided by this study represent a resource to facilitate future clinical investigations to improve the treatment of PM.
> 
> SIGNIFICANCE: Pharmacogenomic characterization of a cell line biobank provides a valuable resource on drug sensitivity in mesothelioma and identifies entinostat as a promising therapeutic option, particularly in combination with immune checkpoint inhibitors.

> **中文摘要：**
> 【未加标签】胸膜间皮瘤（PM）迫切需要有效的治疗手段。本研究旨在基于PM的分子异质性，通过药物再利用策略识别潜在治疗方案。我们对一大队列患者来源的原代PM细胞系（n = 58）进行了多组学研究，并开展了一个多步骤药理学研究，从使用11株细胞系对1,327种化合物进行大规模药物筛选开始，以筛选感兴趣的药物。综合多组学分析表明，该细胞系队列的分子图谱很好地再现了肿瘤中的主要特征，并揭示了PM的重要分子特性。大规模药物筛选鉴定出233种具有活性的化合物，这些化合物归属于常见的治疗类别。对35种候选化合物的后续验证强调了一个由12种药物组成的子集，其疗效优于标准化疗，其中包括恩替莫司他（entinostat）和氟伐他汀（fluvastatin），其治疗活性与分子肉瘤样表型、BAP1突变及YAP/TAZ活性相关。重要的是，这两种化合物在二维和三维培养模型中显示出相同的疗效，而在免疫健全小鼠模型中，单次使用恩替莫司他可较氟伐他汀和标准顺铂—培美曲塞化疗获得更优的生存获益，后两者表现出相似的抗肿瘤效果。值得注意的是，恩替莫司他可增强基于抗PD-1抗体的免疫治疗效果。恩替莫司他与抗PD-1联合治疗甚至在多只小鼠中使肿瘤完全清除，并对肿瘤细胞再植入产生免疫保护作用。总体而言，本研究提供的药物敏感性数据为未来旨在改善PM治疗的临床研究提供了宝贵资源。
> 
> 【重要性】对细胞系生物样本库的药物基因组学特征分析为了解间皮瘤药物敏感性提供了宝贵资源，并鉴定出恩替莫司他作为一种有前景的治疗选择，特别是在与免疫检查点抑制剂联合使用时。

### 第二部分 AI 大师评价

该研究以胸膜间皮瘤为研究对象，通过多组学与大规模药物筛选相结合的方法，探索药物再利用潜能。作者建立了58株患者来源细胞系，系统分析其分子特征及药物敏感性，从超过千种化合物中甄别出显著活性药物。研究发现恩替莫司他在体内外均表现出优越的疗效，并可与抗PD-1免疫治疗形成协同，甚至实现肿瘤清除。该工作为间皮瘤精准治疗提供了新的药理学资源和候选方案，但其转化至临床仍需进一步验证。

---

## 38. CRB2 激活表观遗传轴以促进头颈部鳞状细胞癌中的铁死亡

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40991301)
**期刊：** Cancer research
**PMID：** 40991301
**DOI：** 10.1158/0008-5472.CAN-24-3866

### 第一部分 原文与翻译

**英文原标题：** CRB2 Activates an Epigenetic Axis to Promote Ferroptosis in Head and Neck Squamous Cell Carcinoma.

> **英文摘要：**
> UNLABELLED: Therapeutic activation of ferroptosis is a potential strategy to induce cell death in cancer. Deciphering the epigenetic regulation of ferroptosis could provide insights into effective approaches for enhancing ferroptosis in cancer cells. In this study, we identified CRB2 as an epigenetic modulator of ferroptosis in head and neck squamous cell carcinoma (HNSCC). CRB2 expression correlated with the expression of ferroptosis-related genes and improved prognosis in patients with HNSCC. Ferroptosis inducers erastin and RSL3 significantly increased CRB2 expression, and overexpression of CRB2 sensitized HNSCC to ferroptosis, suppressing growth in vitro and in vivo. CRB2 upregulation led to an increase in the dimethylation of histone H4 lysine 20 in the promoter region of the ferroptosis inhibitor SLC7A11, which epigenetically inhibited its transcription and induced ferroptosis in HNSCC. Mechanistically, CRB2 hindered the interaction between the E8A isoform of the histone lysine demethylase LSD1 and the deubiquitinase USP7, thereby facilitating the degradation of LSD1(E8A) and subsequently increasing histone H4 lysine 20 dimethylation levels. Taken together, these results indicate that CRB2 stimulates ferroptosis by activating an epigenetic axis, suggesting that the upregulation of CRB2 is a potential therapeutic strategy for HNSCC.
> 
> SIGNIFICANCE: CRB2 epigenetically inhibits SCL7A11-GPX4 signaling to promote ferroptosis and suppress tumor growth in head and neck squamous cell carcinoma, providing insights that could guide ferroptosis-activating treatment approaches.

> **中文摘要：**
> 摘要：铁死亡的治疗性激活是一种用于诱导癌细胞死亡的潜在策略。阐明铁死亡的表观遗传调控机制有助于发现增强癌细胞铁死亡的有效方法。在本研究中，我们鉴定出 CRB2 是头颈部鳞状细胞癌（HNSCC）中铁死亡的表观遗传调节因子。CRB2 的表达与铁死亡相关基因的表达呈正相关，并与 HNSCC 患者的预后改善相关。铁死亡诱导剂 erastin 和 RSL3 显著提高了 CRB2 的表达，而 CRB2 的过表达使 HNSCC 对铁死亡的敏感性增加，从而在体内外均能抑制肿瘤生长。CRB2 的上调导致铁死亡抑制因子 SLC7A11 启动子区域组蛋白 H4 第 20 位赖氨酸的二甲基化增加，从而在表观遗传水平上抑制其转录，诱导 HNSCC 中的铁死亡。从机制上看，CRB2 阻止了组蛋白赖氨酸去甲基化酶 LSD1 的 E8A 亚型与去泛素化酶 USP7 之间的相互作用，从而促进 LSD1(E8A) 的降解，并进一步增加组蛋白 H4K20 的二甲基化水平。综上所述，这些结果表明，CRB2 通过激活表观遗传轴来促进铁死亡，提示 CRB2 的上调可能是 HNSCC 的一种潜在治疗策略。
> 
> 重要性：CRB2 通过表观遗传方式抑制 SCL7A11-GPX4 信号通路，从而促进铁死亡并抑制头颈部鳞状细胞癌的肿瘤生长，为铁死亡激活型治疗策略提供了新的思路。

### 第二部分 AI 大师评价

该研究旨在揭示 CRB2 在调控头颈部鳞状细胞癌铁死亡中的表观遗传机制。作者通过体内外实验发现 CRB2 可上调组蛋白 H4K20 二甲基化、下调铁死亡抑制因子 SLC7A11 的转录，从而促进铁死亡并抑制肿瘤生长。此外，研究揭示了 CRB2-LSD1(E8A)-USP7 通路在此过程中的调控关系。该发现为利用表观遗传手段增强铁死亡治疗提供了新的靶点，但仍需进一步验证其在临床转化中的安全性与有效性。

---

## 39. MEN1通过破坏CD44可变剪接促进铁死亡以抑制肺癌发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40991294)
**期刊：** Cancer research
**PMID：** 40991294
**DOI：** 10.1158/0008-5472.CAN-25-0021

### 第一部分 原文与翻译

**英文原标题：** MEN1 Promotes Ferroptosis by Disrupting CD44 Alternative Splicing to Suppress Lung Cancer.

> **英文摘要：**
> UNLABELLED: Ferroptosis is a characteristic form of cell death triggered by excessive iron-dependent reactive oxygen species (ROS) that plays an important role in suppressing tumor development. In this study, we identified MEN1 as a driver of ferroptosis in lung cancer. MEN1 facilitated lipid ROS generation and sensitized lung cancer cells to ferroptosis by perturbing CD44 precursor messenger RNA splicing. CD44 variant isoforms were highly expressed and correlated with poor prognosis in human lung cancers. Loss of Men1 profoundly accelerated the progression of mutant Kras-driven lung adenocarcinoma and promoted the accumulation of CD44 variant isoforms. Mechanistically, MEN1 maintained a relatively slow RNA polymerase II elongation by controlling the release of PAF1 from the CD44 precursor messenger RNA, which in turn prevented the inclusion of CD44 variable exons. Furthermore, CD44 variable exon 6-interfering peptides effectively abrogated the growth and metastasis of established MEN1-deficient tumors by activating ferroptosis. Collectively, this study unveils a mechanism of tumor suppression based on MEN1 regulation of CD44 alternative splicing, ROS production, and ferroptosis induction.
> 
> SIGNIFICANCE: MEN1 governs CD44 alternative splicing and CD44 variant generation to activate ferroptosis and disrupt lung cancer development, highlighting the potential of targeting this axis to treat MEN1-deficient tumors.

> **中文摘要：**
> 未加标签摘要：铁死亡是一种由过量依赖铁的活性氧（ROS）诱导的特征性细胞死亡形式，在抑制肿瘤发展中发挥重要作用。在本研究中，我们鉴定出MEN1是肺癌中铁死亡的驱动因子。MEN1通过扰乱CD44前体信使RNA剪接，促进脂质ROS的生成，并使肺癌细胞对铁死亡更为敏感。CD44变异异构体在人体肺癌中高表达，并与不良预后密切相关。Men1缺失显著加速了由Kras突变驱动的肺腺癌进程，并促进了CD44变异异构体的积累。从机制上讲，MEN1通过调控PAF1从CD44前体信使RNA的释放来维持相对缓慢的RNA聚合酶II延伸，从而阻止CD44可变外显子的包含。此外，针对CD44可变外显子6的干扰肽通过激活铁死亡，有效抑制了已形成的MEN1缺失肿瘤的生长和转移。综上所述，本研究揭示了一个基于MEN1调控CD44可变剪接、ROS生成及铁死亡诱导的肿瘤抑制机制。
> 
> 研究意义：MEN1通过调控CD44可变剪接及其变异体的产生来激活铁死亡并干扰肺癌发展，提示靶向该通路有望治疗MEN1缺陷型肿瘤。

### 第二部分 AI 大师评价

该研究确定MEN1作为调控铁死亡的关键分子，通过干扰CD44的可变剪接促进脂质过氧化并抑制肺癌进展。作者结合分子机制实验和动物模型，揭示MEN1维持RNA聚合酶II延伸速率、调节PAF1释放并防止CD44变异外显子插入的作用。研究创新性在于首次建立了MEN1–CD44剪接–铁死亡的肿瘤抑制轴，为MEN1缺失型肺癌的治疗提供潜在靶点。局限性可能在于临床样本验证和特异性调控机制仍需进一步研究。

---

## 40. ZNF296通过抑制免疫刺激基因驱动上皮性癌症的免疫逃逸

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40991281)
**期刊：** Cancer research
**PMID：** 40991281
**DOI：** 10.1158/0008-5472.CAN-25-0153

### 第一部分 原文与翻译

**英文原标题：** ZNF296 Drives Immune Evasion in Epithelial Cancers by Repressing Immune Stimulatory Genes.

> **英文摘要：**
> UNLABELLED: Resistance to immune-mediated destruction is a fundamental hallmark of cancer. Although several mechanisms have been identified that facilitate immune evasion, the transcriptional programs that orchestrate this process remain poorly understood. In this study, through a genome-wide CRISPR activation screen in human cancer cells subjected to NK cell-mediated killing, we identified ZNF296, a transcription factor highly expressed in epithelial cancers, as a key driver of tumor resistance to both NK and cytotoxic T-cell-mediated immunity. In mouse models, inhibition of ZNF296 significantly enhanced both NK and T-cell-mediated antitumor immunity, leading to a marked reduction in metastasis and increased infiltration of immune cells into the tumor microenvironment. Mechanistically, ZNF296 induced strong transcriptional repression of IFN-stimulated genes and key immunostimulatory ligands critical for NK and T-cell-mediated cytotoxicity. At the molecular level, ZNF296 directly interacted with and recruited the NuRD chromatin remodeling and deacetylase complex to the promoters of its target genes to suppress expression. Notably, treatment with low-dose romidepsin, an FDA-approved inhibitor targeting histone deacetylase 1, a core component of the NuRD complex, effectively restored NK and T-cell-mediated killing in cancer cells with high ZNF296 expression. Collectively, these findings establish ZNF296 as a key regulator of immune evasion, driving resistance to both NK and T-cell-mediated antitumor immunity, and highlight its potential as a therapeutic target to overcome immune resistance in epithelial cancers.
> 
> SIGNIFICANCE: ZNF296 is a transcriptional regulator that enables cancer cells to evade immune surveillance, offering possibilities for developing treatments that enhance the ability of the immune system to eliminate cancer cells.

> **中文摘要：**
> 未标注：对免疫介导破坏的抵抗是癌症的一个基本特征。尽管已有若干机制被发现可促进免疫逃逸，但调控这一过程的转录程序仍知之甚少。在本研究中，通过在接受NK细胞介导杀伤的人癌细胞中进行全基因组CRISPR激活筛选，我们鉴定出ZNF296这一在上皮性癌症中高表达的转录因子，作为肿瘤对NK细胞和细胞毒性T细胞介导免疫的关键抵抗驱动因子。在小鼠模型中，抑制ZNF296显著增强了NK细胞和T细胞介导的抗肿瘤免疫，导致转移显著减少，并增加了免疫细胞在肿瘤微环境中的浸润。从机制上看，ZNF296对IFN刺激基因以及对NK和T细胞介导细胞毒性至关重要的关键免疫刺激配体实施了强烈的转录抑制。在分子水平上，ZNF296直接与NuRD染色质重塑及去乙酰化复合物相互作用并将其招募到靶基因启动子区域以抑制其表达。值得注意的是，用低剂量的romidepsin（一种FDA批准的靶向组蛋白去乙酰化酶1、即NuRD复合物核心组分的抑制剂）治疗，能够有效恢复ZNF296高表达癌细胞中NK与T细胞介导的杀伤作用。综上所述，这些发现确立了ZNF296作为免疫逃逸关键调控因子的角色，它驱动了对NK与T细胞介导的抗肿瘤免疫的抵抗，并突出了其作为克服上皮性癌症免疫耐受潜在治疗靶点的可能性。
> 
> 意义：ZNF296是一种转录调控因子，使癌细胞能够逃避免疫监视，为开发增强免疫系统清除癌细胞能力的治疗策略提供了可能。

### 第二部分 AI 大师评价

该研究通过全基因组CRISPR激活筛选发现ZNF296是促进上皮性癌症免疫逃逸的关键转录因子。作者揭示ZNF296通过招募NuRD复合物抑制IFN刺激和免疫活化相关基因，从而削弱NK与T细胞的杀伤作用。动物实验显示，抑制ZNF296可增强抗肿瘤免疫并减少转移。研究创新地连接了转录调控网络与免疫逃逸机制，并提出了利用HDAC抑制剂逆转这一过程的潜在治疗策略。其局限性可能在于尚需进一步验证在人类肿瘤微环境中的临床可行性。

---

## 41. 整合ctDNA动态与序贯类器官药物筛选以提升乳腺癌治疗效果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40991260)
**期刊：** Cancer research
**PMID：** 40991260
**DOI：** 10.1158/0008-5472.CAN-25-0608

### 第一部分 原文与翻译

**英文原标题：** Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy.

> **英文摘要：**
> UNLABELLED: Dynamic changes in ctDNA variant allele frequency reflect real-time therapeutic efficacy. Timely treatment modification guided by ctDNA variant allele frequency may enable precision selection of optimized regimens to counteract evolving resistance in breast cancer. In this study, we developed a therapeutic approach integrating ctDNA dynamics with sequential organoid drug screening to optimize breast cancer treatment. Targeted deep sequencing on plasma samples from 71 patients with breast cancer revealed that ctDNA clearance correlates with improved disease-free survival. Additionally, analysis of 40 breast cancer organoid models demonstrated the potential of organoid culture supernatants for comprehensive mutation profiling and drug sensitivity testing. Together, these findings suggest that combining ctDNA monitoring with organoid-based drug screening can guide adjustments to treatment strategies, offering a promising solution to optimize patient outcomes.
> 
> SIGNIFICANCE: Monitoring circulating tumor DNA in combination with drug screening of organoids enables dynamic, personalized breast cancer therapy adjustments to overcome resistance and improve treatment efficacy.

> **中文摘要：**
> 未加标签：ctDNA变异等位基因频率的动态变化反映了实时的治疗效果。通过ctDNA变异等位基因频率指导的及时治疗调整，可能实现精准选择优化方案，以应对乳腺癌中不断演化的耐药性。在本研究中，我们开发了一种治疗策略，将ctDNA动态变化与序贯类器官药物筛选相结合，以优化乳腺癌治疗。对71例乳腺癌患者血浆样本进行的靶向深度测序显示，ctDNA清除与无病生存期的改善相关。此外，对40种乳腺癌类器官模型的分析表明，类器官培养上清液在综合突变谱分析和药物敏感性测试方面具有潜力。总体而言，这些发现提示，将ctDNA监测与基于类器官的药物筛选相结合，可指导治疗策略的调整，为优化患者预后提供了一种有前景的解决方案。
> 
> 重要性：将循环肿瘤DNA的监测与类器官药物筛选相结合，可以实现乳腺癌治疗的动态化、个体化调整，从而克服耐药性并提高治疗效果。

### 第二部分 AI 大师评价

该研究旨在通过整合ctDNA动态监测与序贯类器官药物筛选，提升乳腺癌治疗的精准性与疗效。研究基于患者血浆ctDNA深度测序与类器官模型的药物敏感性分析，验证了ctDNA清除与无病生存期改善之间的关联。该策略实现了分子水平的动态疗效监控与功能性的药物筛选结合，为实时优化治疗方案提供了新范式。创新性在于双层动态监控体系的构建，但仍需在大规模临床验证和标准化流程方面进一步完善。

---

## 42. 压力通过改变中性粒细胞分化促进乳腺癌肺转移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40991232)
**期刊：** Cancer research
**PMID：** 40991232
**DOI：** 10.1158/0008-5472.CAN-25-1763

### 第一部分 原文与翻译

**英文原标题：** Stress Promotes Lung Metastasis in Breast Cancer by Altering Neutrophil Differentiation.

> **英文摘要：**
> UNLABELLED: Mental stress is widely recognized as a significant risk factor for breast cancer, exerting detrimental effects on both progression and prognosis. Herein, we investigated the role of stress in regulating breast cancer metastasis. In genetically engineered and transplantation breast cancer mouse models, chronic stress stimulation increased tumor growth and lung metastasis. Single-cell RNA sequencing analysis of the premetastatic lung microenvironment revealed induction of a previously unrecognized subtype of cancer stress-primed (CSP) neutrophils, characterized by the overexpression of Ccl3, Ccl4, Cxcl2, Il1r2, and Cebpb. Pseudotime trajectory analysis demonstrated that chronic stress caused a shift of neutrophils from the cancer-primed neutrophil subtype to the CSP subtype in the lung. Activation of the glucocorticoid receptor NR3C1 by the stress hormone corticosterone induced expression of Cebpb in neutrophils, which then promoted transcription of Ccl3 and Ccl4. The differentiation of neutrophils into the CSP subtype promoted lung metastasis of CCR1+ breast cancer cells via CCL3/CCL4-mediated recruitment. Targeting this axis using an anti-Ly6G antibody to deplete neutrophils, a CRISPR/Cas9-mediated approach to conditionally knock out Ccl3/Ccl4 in neutrophils, and BX471 treatment to inhibit CCR1 in cancer cells all significantly reduced breast cancer lung metastasis. Together, this study not only demonstrates a stress-neutrophil-cancer axis that promotes lung metastasis in breast cancer but also provides potential strategies for reducing lung metastasis by targeting CSP neutrophils or CCR1+ breast cancer cells.
> 
> SIGNIFICANCE: Stress induces a neutrophil subtype in the lungs that secretes CCL3 and CCL4 to stimulate metastasis of breast cancer cells by activating CCR1, offering potential strategies for preventing or treating metastasis.

> **中文摘要：**
> 未加标签摘要：心理压力被广泛认为是乳腺癌的重要风险因素，对其进展和预后均有不利影响。在本研究中，我们探讨了压力在调节乳腺癌转移中的作用。在基因工程和移植性乳腺癌小鼠模型中，慢性压力刺激增加了肿瘤生长和肺转移。对转移前肺微环境的单细胞RNA测序分析显示，诱导了一种先前未被识别的癌症压力预激（CSP）中性粒细胞亚型，其特征是Ccl3、Ccl4、Cxcl2、Il1r2和Cebpb的过表达。伪时间轨迹分析表明，慢性压力导致中性粒细胞从癌症预激亚型向CSP亚型在肺中发生转变。压力激素皮质酮通过激活糖皮质激素受体NR3C1，诱导中性粒细胞中Cebpb的表达，进而促进Ccl3和Ccl4的转录。中性粒细胞向CSP亚型的分化通过CCL3/CCL4介导的募集促进CCR1+乳腺癌细胞的肺转移。通过使用抗Ly6G抗体清除中性粒细胞、采用CRISPR/Cas9介导的条件性敲除中性粒细胞中的Ccl3/Ccl4，以及使用BX471抑制癌细胞中CCR1的活性，这一信号轴的靶向干预均显著减少了乳腺癌肺转移。总体而言，本研究不仅揭示了促进乳腺癌肺转移的“压力–中性粒细胞–癌症”轴，还提供了通过靶向CSP中性粒细胞或CCR1+乳腺癌细胞以减少肺转移的潜在策略。
> 
> 意义：压力在肺中诱导一种分泌CCL3和CCL4的中性粒细胞亚型，该亚型通过激活CCR1促进乳腺癌细胞转移，为防治转移提供了潜在策略。

### 第二部分 AI 大师评价

本研究系统揭示了慢性心理压力通过改变中性粒细胞分化状态促进乳腺癌肺转移的分子机制。作者利用基因工程小鼠模型、单细胞转录组测序及轨迹分析阐明了压力通过NR3C1–Cebpb–CCL3/CCL4–CCR1信号轴驱动“压力预激”中性粒细胞的形成与招募作用。研究创新性地提出了“压力–免疫–转移”新轴，链接神经内分泌信号与肿瘤微环境免疫塑形。其局限性在于部分数据来自动物模型，临床可转化性仍需进一步验证。总体上，该研究为乳腺癌转移的应激干预提供了重要理论依据和潜在治疗靶点。

---

速递结束，祝您工作愉快！